Dr Michael Pollak

Position:

• Prof, Oncology, McGill University
• Director, Cancer Prevention, McGill University

Credentials:

• MD

Websites:

• http://www.mcgill.ca/pollak-lab/
• http://www.drpollakassaylab.ca/

Biography:

MICHAEL POLLAK

CURRICULUM VITAE

 

Home Address Office Address

4889 Mira Rd. Department of Oncology

Montreal, Quebec, Canada Jewish General Hospital / McGill University

H3W 2B7 3755 Côte Ste-Catherine Rd.

Montreal, Quebec, Canada

Tel: (514) 486-7412 H3T 1E2

Tel.: (514) 340-8222 ext. 5530 (office)

(514) 340-8222 ext. 5527 (secretary)

(514) 340-8222 ext. 4139 (lab)

(514) 340-8248 (clinic)

Fax: (514) 340-8600

E-mail: michael.pollak@mcgill.ca

Revised February 2012

Michael Pollak, MD

HIGHLIGHTS OF CV

Ø Experienced clinician-scientist certified in Internal Medicine and Medical Oncology.

Ø Active research program, with > $15 million peer-reviewed funding awarded for laboratory research despite an appointment that has included substantial time in clinical practice.

Ø Leadership roles in national and international research networks

Ø Teaching activities at undergraduate and graduate levels highly rated.

Ø Extensive clinical trial and translational research experience.

Ø Experience in managing private sector - academic - government collaborations in oncology.

Ø More than 15, 450 citations of his scientific contributions

PERSONAL DATA

Date of Birth August 8, 1952

Place of Birth Montreal, Quebec, Canada

Marital Status Married with three children

Languages English, French

EDUCATION

UNDERGRADUATE:

1970	“Cum Laude” Graduate of Selwyn House School, Montreal, Quebec
1970	“Cum Laude” Certificate, Ecole de Français, Montreux, Switzerland
1973	University Entrance Scholarship Diplome d'Etudes de College (Science)
1973	Dip. Collegial Studies, McGill University, Biology and Computer Science

MEDICAL:

1977	M.D. McGill University

POST-GRADUATE MEDICAL TRAINING:

1977-78	Rotating Internship St. Michael’s Hospital, University of Toronto
1979-80	Internal Medicine Residency St. Michael’s Hospital, University of Toronto
1980-81	Internal Medicine Residency Toronto General Hospital, University of Toronto
1981-83	Internal Medicine and Medical Oncology Residencies Princess Margaret Hospital and associated teaching units, University of Toronto

EXTRA-CURRICULAR ACTIVITIES AS RESIDENT:

1980-81	President, House-staff Association, Toronto General Hospital and House-staff Representative to TGH Medical Advisory Board
1980-82	Part-time consultative position with IBM Canada Ltd. as “Health Industry Specialist” (with approval of Dept. of Medicine, University of Toronto)

POST-RESIDENCY RESEARCH FELLOWSHIP AND ACTIVITIES:

1983-85	Terry Fox Fellowship awarded by National Cancer Institute of Canada and Ontario Cancer Institute (laboratory of Dr. Ron Buick)
1983-85	Associate Physician, Department of Medicine (Division of Hematology/Oncology), Toronto General Hospital, and Lecturer, Department of Medicine, University of Toronto
1984-85	Part-time Clinical Staff Appointment Department of Medicine, Woman's College Hospital, Toronto

PROFESSIONAL CERTIFICATIONS

1978	Medical Council of Canada Certification
1978	National Board of Medical Examiners, USA Certification
1978	General License for Medical Practice, Ontario
1978	General License for Medical Practice, British Columbia
1982	General License for Medical Practice, California
1982	FRCPC Specialty Certificate in Internal Medicine (Canada)
1984	Elected to membership of ASCO (American Society of Clinical Oncology)
1985	General License for Medical Practice, Quebec
1985	Elected to membership of AACR (American Association for Cancer Research)
1985	Certification as Specialist (Internal Medicine), Quebec
1987	FRCPC Specialty Certificate in Medical Oncology (Canada)
1994	Certification as Specialist (Medical Oncology), Quebec (This Specialty first recognized by Corporation Professionelle des Medecins in 1994.)

APPOINTMENTS

UNIVERSITY:

1984	Lecturer, Department of Medicine, University of Toronto
1985-	Project Director, Lady Davis Institute for Medical Research
1985-90	Assistant Professor, Department of Medicine, McGill University
1985-90	Assistant Professor, Cancer Center, McGill University
1990-	Associate member, McGill AIDS Center
1990-	Member, Division of Experimental Medicine, Department of Medicine, McGill University
1991-96	Associate Professor, Departments of Oncology and Medicine, McGill University
1993-99	Riesman Clinician-Scientist, Department of Oncology, Jewish General Hospital and McGill University (replaced by Research Chair, see below)
1995-	“Chercheur-boursier clinicien” award from Fonds de la Recherche en santé du Québec (FRSQ)
1997-	Board of Directors, Center for Translational Research in Oncology, McGill University
1997-	Scientific Advisory Board, Center for Translational Research in Oncology, McGill University
1997-	Professor (tenured), Departments of Medicine and Oncology, McGill University
1998-	“Chercheur-boursier clinicien” (senior) award from FRSQ
1999-	Alexander-Goldfarb Research Chair in Medical Oncology, McGill University
2002-	“Chercheurs-Nationaux” award from FRSQ (ranked first in this competition)
2002-	Director, Cancer Prevention Program, Department of Oncology, McGill University

HOSPITAL:

1978	General Practice Locum, Windermere District Hospital, Invermere, British Columbia (May to September)
1981-84	Emergency Room Privileges, J.O. Ruddy General Hospital, Whitby, Ontario, and part-time staff, Ajax-Pickering Hospital, Ajax, Ontario (weekend work during residency training)
1984	Part-time Staff, Division of Oncology, Woman's College Hospital Toronto (in conjunction with Terry Fox Fellowship at Ontario Cancer Institute)
1985-	Staff Physician, Department of Internal Medicine and Oncology, Jewish General Hospital, with following clinical responsibilities: 1985-89 Oncology Consultation Service - : 6 months/year 1989- Oncology Consultation Service - : 4 months/year 1986-88 General Medicine Service - : 2 months/year 1985- Oncology Outpatient Service - : approx. 40 patients/week 1985- Oncology Inpatient Service - : approx. 2 admissions/week
1994-99	Co-director, Tumor Board, Jewish General Hospital
1997-	Member, Department of Endocrinology, Jewish General Hospital
1997-	Director, Cancer Prevention Research Unit, Department of Oncology

AWARDS

1973	University entrance scholarship, McGill
1983	Terry Fox Fellowship Award, Ontario Cancer Institute
1993	Riesman Career Scientist Award, Department of Oncology McGill University and Jewish General Hospital
1995	FRSQ Clinician Scientist award
1997	Promotion to Full Professor (tenured), McGill University
1998	FRSQ Senior Clinician Scientist award
1999	McGill University Scientist of the year­­­­­­–1998, “McGill Reporter”
1999	Alexander-Goldfarb Chair in Medical Oncology, McGill University
2002	FRSQ National Scientist award (ranked first in this competition)

TEACHING

MEDICAL STUDENTS AND RESIDENTS:

1985-	Supervision and teaching of Clinical Fellows, residents, interns, and medical students attending my outpatient clinic (average 8 months/year)
1986-99	Supervision and teaching of Clinical Fellows, residents, interns, and medical students on teaching ward with respect to Medical Oncology (4 months/year)
1986-87	Clinical Skills Examiner–3rd year medical students
1986-88	Supervision and teaching of on General Medical Ward with respect to General Internal Medicine. (2 months/year)
1990	Supervision of S Malaab, Canadian Association of Medical Oncology (CAMO) Award for best trainee presentation at Royal College Annual Meeting, Toronto
1994	Supervision of V Thanos, pre-medical student summer research project
1994	Supervision of A Jacobson, medical student summer research project
1994-95	Thesis advisor, Catherine Phelan, Visiting PhD Student, Karolinska Institute Ph.D. granted 1997
1995	Supervision of J Rosenblatt, medical student summer research project
1995	Education Committee, Department of Oncology
1995	Undergraduate Medical Education: small group teaching in Biology of Oncology
1996	Examiner, Radiation therapy residents
1996	Participant, Faculty Teaching Skills Workshop
1997	Whole class teaching for medical students, Oncology Therapeutics
1997	Small group teaching, second year medical students
1999	Oncology Service Teaching Rounds, Dept. of Medicine, Jewish General Hospital
2002-	Small group teaching for medical students, Cancer Prevention
2002-	Whole class undergrad medical student lectures in cancer prevention.
2002-	Dept of Oncology ‘clinical science for basic scientists’ lecture series

Ph.D. AND POST-DOCTORAL STUDENTS:

1992-97	Supervision of post-doctoral fellow H Hung
1995-99	Supervision of PhD student Tara Nickerson
1997-2004	Supervision of PhD student Yuhong Lu
1999-2006	Supervision of PhD student Randy Levitt
1999-2002	Supervision of post-doctoral fellow Xiaolin Zi
1999-	Supervision of post-doctoral fellow Marie-José Blouin
2000-06	Supervision of post-doctoral fellow Anne Camirand
2003-	Supervision of post-doctoral fellow Mahvash Zakikhani
2006-07	Supervision of post-doctoral fellow Matthew Cunningham
2006-	Supervision of PhD student Matei Mireuta
2006-11	Supervision of PhD student Carolyn Algire
2007-09	Supervision of masters’ student Carly Dool
2007-09	Supervision of visiting research fellow Esther Piura (Tel Aviv University)
2008-09	Supervision of post-doctoral fellow Takamitsu Inoue
2009-11	Supervision of masters’ student Haider Mashhedi
2010-	Supervision of masters’ student Shiva Javeshghani
2010-	Supervision of post-doctoral fellow Henning Hvid
2011-	Supervision of masters’ student Nader Toban

Ph.D. THESIS AND COMPREHENSIVE EXAM COMMITTEES

1990	H Wang (Division of Surgical Research)
1993	R Schecter (Department of Experimental Medicine)
1997	N Giannoukakis (Department of Experimental Medicine)
1998	L Long (Department of Experimental Surgery)
1999	L Zi (Department of Pharmacology)
2002	C Hamelin (Department of Pediatrics), Université de Montreal

OTHER CONTRIBUTIONS

COLLABORATIVE CLINICAL TRIAL GROUP ACTIVITIES

NCI (USA) Cancer Therapy Evaluation Program

Investigator number 14676

NSABP (National Surgical Adjuvant Breast and Bowel Project)

Participant, 1985-

Appointed to Biological Markers Committee, 1987

B29 Tamoxifen octreotide adjuvant breast cancer trial design committee, 1995-6

Appointed to breast cancer management committee, 1997

NCIC (National Cancer Institute of Canada)

Participant, 1985-

Appointed to breast site committee, 1995

Principal Investigator, MA14 adjuvant breast cancer trial 1996-

Translational Science Leader, colorectal committee, 2008 –

Breast IND group, 2009 -

CALGB (Cancer and Leukemia Group B)

Participant, 1995-97

SWOG (South West Oncology Group)

Consultant, regarding translational research component of the Prostate Cancer

Prevention Trial, 2001-

In my clinical practice, I enroll patients in clinical trials coordinated by the above groups as well as others arranged locally.

MANUSCRIPT REVIEW FOR SCHOLARLY PUBLICATIONS

Proceedings of the National Academy of Sciences (USA)

Journal of Clinical Investigation

Cancer

Cancer Research

Gene

Clinical Cancer Research

Cell Growth and Differentiation

Oncology Research

Proceedings of the Society for Experimental Biology and Medicine

Peptides

American Journal of Obstetrics and Gynecology

Journal of Clinical Endocrinology and Metabolism

Endocrinology

International Journal of Cancer

Biotechniques

Journal of Molecular Endocrinology

Journal of the National Cancer Institute

Gynecologic Oncology

Lancet

New England Journal of Medicine

GRANT PANELS

1990	Cancer Research Society, Montreal, Medical Advisory Board
1989-90	National Cancer Institute of Canada, Review Panel J, Biology/endocrinology
1994	MRC Canada, Chairman, Site Review panel for a $1.2 million research program
1994	US Army Breast Cancer Program: member, Cancer Biology grant review panel, Receptor biology
1996	US Army Breast Cancer Program: member, Cancer Endocrinology review panel
1996-98	National Cancer Institute of Canada, Review Panel J, Molecular epidemiological and clinical correlative studies
1998	MRC Canada, Chairman of a site review panel for a multimillion-dollar research program (declined)
1998	NCIC, Member of a site review panel for a multimillion dollar research program
1997-99	Israel Cancer Research Fund
2002-	NIH/ NCI grant review study sections (cancer prevention, epidemiology of cancer), invited member
2005-	Israel Cancer Research Fund
2005-	Prostate Cancer Research Foundation of Canada
2005-	Site review responsibilities in Ireland and Sweden

AD HOC GRANT REVIEWS

I have been asked to review grant applications submitted to:

Cancer Research Society

National Cancer Institute of Canada

MRC Canada and CIHR

FRSQ

Manitoba Health Research Council

NIH/NCI (USA)

New South Wales (Australia) Cancer Society

ADMINISTRATIVE RESPONSIBILITIES

National and International

1. Scientific Congress Organization

1992	Program Committee, International Somatostatin Symposium, Monte Carlo
1993	Program Committee, National Breast Cancer Forum, Montreal, Quebec
1995	Program Committee, International Somatostatin Symposium, Sorrento, Italy
1999	Coordinator and Program Committee, First International Workshop on growth hormone, insulin-like growth factors, and neoplasia, Boston, October
1999	Chair, Clinical Endocrinology Section, American Association for Cancer Research (AACR) meeting, San Francisco, April
2002	Chair, Scientific Committee, Fondation Chagnon International Symposium on Cancer Prevention, Montreal, November
2006	Chair, Scientific Committee, Workshop on “Milk consumption, hormones, and human health”, Harvard University, Boston, October
2006	Program Committee, St. Gallen International Cancer Prevention Symposium, St. Gallen, Switzerland, February
2008	Program Committee, St. Gallen International Cancer Prevention Symposium, St. Gallen, Switzerland, February
2008	Organizing Committee, International symposium on insulin-like growth factors, Genoa, Italy October, 2008
2011	Organizer (with Drs Craig Thompson and James Watson) of Banbury Centre meeting (Cold Spring Harbor Laboratory) on “Metformin and Neoplasia”

2. Multicenter Clinical Trial Organization

1995-

Principal Investigator, NCIC MA-14 Project. This clinical trial involves a partnership between NCIC Clinical Trials Group, CIHR, and NOVARTIS. It established one of the first major clinical trial-associated biobanks (DNA, serum, tissue) linked to a patient outcome database.

3. Miscellaneous

1998	Canadian Breast Cancer Research Initiative, invited participant in programmatic review.
2002-07	Scientific Advisory Committee, Canadian Breast Cancer Research Alliance
2008-	Editorial Board, Cancer Prevention Research (AACR Journal)
2011	Scientific Advisory Board, Next Generation Sequencing Panel, Lama Control Agency of British Columbia and University of British Columbia

University

1. McGill Cancer Center—Institutional Review Board (IRB) liaison regarding all consent forms for oncology clinical trials at McGill (1986-1987)

2. Chairman, Endocrine—Biologicals Section of Clinical Trials Group, Department of Oncology (1992- 1995)

In this capacity, I arranged for the Department to participate in various clinical trials in collaboration with pharmaceutical companies. I also have established priorities for clinical trials proposed. All trials I have proposed and coordinated have met accrual targets and generated income for the University in excess of expenses.

3. Director, Division of Cancer Prevention, Department of Oncology. (2002- )

Hospital

1. Clinical Trials Administration in Oncology at JGH

1992-2000	Recruiting of staff. I identified and recommended individuals for data manager - clinical trial nurse teams.
1992-2000	Arranging of laboratory support for clinical trials. I arranged for special handling and processing of blood and tissue samples obtained in connection with clinical trials run in the Oncology Clinic. This enabled us to participate in trials requiring such samples.

2. Co-Chair, Tumor Board, JGH, 1994-

This function involves both teaching and service functions. New patients are discussed by a multidisciplinary audience including members of various surgical specialties, radiotherapists, and medical oncologists. Nurses, pharmacists, data managers, residents, and students also participate. Treatment options are reviewed, particularly with respect to ongoing clinical trials. The Chair helps select cases, leads the discussion, and documents the recommendations of the Tumor Board.

3. Member, Search Committee, Chief, JGH, Dept. of Oncology, 1986

4. Supportive Care Committee, 1986-1994

5. JGH Computerized Patient Information Committee, 1986

6. Chairman, Research Computing Committee, Lady Davis Institute, 2005-

7. Director, Cancer Prevention Research Unit, Jewish General Hospital, 1997-

In this capacity, I act to co-ordinate cancer prevention research activities. We have established a group of laboratory and clinical scientists working in this area. I have recruited a clinician-scientist in the field of cancer genetics to run a clinic for individuals concerned about inherited or acquired cancer risk. In addition to research activities, an information office provides services to the public and to referred clients concerning cancer prevention.

EXAMPLES OF CONTRIBUTIONS TO PUBLIC MEDIA

“Patience needed on cancer cure”, Montreal Gazette, page B3 [op-ed], May 29, 1998

Cancer Research Segment for National Network Distribution (Canadian Broadcasting Corporation), 1998

“McGill Reporter” survey: McGill researcher most cited in public media, 1998

Top-ranked public lecturer at “Minimed” program of JGH, 2007

EXAMPLE OF PUBLIC SECTOR CONSULTING

Member, Health and Welfare Canada Expert Committee on bovine somatotropin, 1998

EXAMPLES OF PRIVATE SECTOR CONSULTING

AND ACADEMIC COLLABORATIONS

(see RESEARCH section)

MISCELLANEOUS AFFILIATIONS

Member, Canadian Medical Association

Member, Ontario Medical Association

Member, Quebec Medical Association

Fellow, Royal College of Physicians and Surgeons of Canada

Member, College of Physicians of Ontario

Member, Federation of Medical Specialists of Quebec

Member, American Society of Clinical Oncology

Member, American Association for Cancer Research

Member, Canadian Society for Clinical Investigation

Member, Canadian Association of Medical Oncologists

Member, Prostate Cancer Research Foundation of Canada

RESEARCH

My research interests concern the role of peptide mitogens in the control of cellular proliferation, and derangements of these control systems in malignancy. I have experience in laboratory, clinical and population-based research.

EXTERNAL SALARY SUPPORT

“Chercheur-boursier clinicien” award (FRSQ) 1995 - 2003: $42,042/year

“Chercheurs Nationaux” award (FRSQ) 2003 – 2008: $65,000/year

RESEARCH GRANT SUPPORT

(A) Laboratory work

(* indicates that Michael Pollak is Principal Investigator or Co-Principal Investigator)

$25,000 1989	*Shyamala G, Kalant N, Pollak M. Mechanisms of diet restriction – related reduction of carcinogen- induced breast cancer in rats. Cancer Research Society of Montreal
$10,000 1989	*Pollak M, Polychronakos C. Support for study evaluating effect of SMS 201-995 on serum IGF-1 levels in cancer patients. Sandoz Canada
$200,000 1989-92	*Pollak M. Role of Somatomedins and EGF in determining the proliferative behavior of human neoplasms. Cancer Research Society of Montreal
$21,000 1991	*Pollak M. Antiestrogen - Somatostatin synergy in animal models of breast cancer. Canadian Breast Cancer Foundation
$186,000 1991-93	*Pollak M, Bell R. Somatomedins-relevance to osteosarcoma. National Cancer Institute of Canada
$20,000 1992	*Pollak M. Octreotide preclinical activity in breast cancer. Sandoz, Basle
$50,000 1992	*Pollak M. Central growth factor lab for analysis of sera collected in international phase II somatostatin clinical trials. Sandoz Research Institute, East Hanover, USA
$130,000 1992-95	*Pollak M. Somatomedins: relationship to endocrine cancer therapies. National Cancer Institute of Canada
$180,000 1994-97	*Bell R, Pollak M. Somatomedins and osteosarcoma. National Cancer Institute of Canada
$32,000 1995-96	*Pollak M. Use of the “lit” mutation to evaluate the growth-hormone-IGF-I axis as a host factor influencing neoplastic behavior. MRC
$293,625 1995-98	*Pollak M. Tumor suppressor properties of the gene encoding mammary derived growth inhibitor.
$346,700 1995-99	*Pollak M. Insulin-like growth factor I in the pathophysiology in neoplasia. National Cancer Institute of Canada
$2,928,000 1996-2001	*Pollak M. Translational research regarding antiestrogen-somatostatin therapy. (This budget includes administration of a multicenter clinical trial and operating funds for associated laboratory studies.) MRC-PMAC program (administered by Medical Research Council, Canada)
$30,000 1997	*Pollak M. Novel biological source metalloproteinase inhibitors: assay in experimental breast cancer metastasis. Canadian Breast Cancer Foundation
$149,625 1997-98	*Pollak M. IGFs and Breast Cancer Risk. National Cancer Institute of Canada
$228,873 1997-2000	*Pollak M, Bell B. IGFs and sarcoma. National Cancer Institute of Canada
$162,972 1997-2000	Pritchard K, and others including Pollak M. A national tumor and data bank for patients in NCIC clinical trials. National Cancer Institute of Canada
$300,698 1997-2000	*Pollak M, Karaplis A. PTHrP in normal breast development. National Cancer Institute of Canada
$110,000 1997-2001	*Pollak M. Contract for collaborative research with Environmental Epidemiology Branch, National Cancer Institute. USA
$460,000 1997-2001	*Pollak M. Subcontract for endocrine epidemiology in relation to cancer risk. National Cancer Institute/ Harvard School of Public Health
$135,000 1998-99	*Pollak M, Eyssen G. Serum markers of IGF physiology and colon cancer risk. National Cancer Institute of Canada
$50,000 1998-99	*Pollak M. Contract research. Sensus Corporation
$240,000 1998-2000	Narod S, Pollak M and others. Prognostic factors for metastatic progression of localized prostate cancer. National Cancer Institute of Canada
$18,000 1998-2000	*Pollak M. Breast Cancer Prevention Based on Hormonal Factors. National Breast Cancer Fund
$306,000 1998-2001	Klotz L and others including Pollak M. Basic science companion laboratory studies to NCIC CTG trial PR-7. National Cancer Institute of Canada
~$1,000,000 1998-2006	Pollak M. Subcontracts for laboratory work awarded to MP by Harvard University (Using NIH funding to Harvard School of Public Health)
$65,000 1999-2000	*Pollak M. Contract research. Axys Pharma
$19,672 1999-2000	*Pollak M. Team-building award, Canada Breast Cancer Research Initiative
$80,000 1999-2001	*Pollak M. Contract research. Diagnostic Systems Limited
$216,900 1999-2001	Narod S and others including Pollak M. The role of serum IGF-I levels and androgen receptor genotype in prostate cancer diagnosis. National Cancer Institute of Canada
$458,016 1999-2002	*Pollak M. Serum markers of IGF physiology and risk of breast, prostate, and colon cancer. National Cancer Institute of Canada
$20,600 * 2000-01	*Pollak M. IGFs and cancer risk in the CARET cohort. Subcontract for Dr. M Spitz.
$18,000 2000-01	*Pollak M. IGF physiology in relation to lung cancer risk and prevention. Subcontract for IGF-I assay work for Dr. M Spitz and collaborators.
$130,000 2000-01	*Pollak M. Subcontract for growth factor assays, US Army/ Physicians’ Health Study
$156,000 2000-01	*Pollak M. Component of NCI (USA) contract N01-CN-95040-46 awarded to Euhus D et al, University of Texas, Dallas. ‘An exploratory study to identify potential surrogate endpoint biomarkers that are modulated by tamoxifen vs placebo in women with an increased risk for breast cancer’
$291,168 2000-02	*Pollak M. Silibinin in prostate cancer chemoprevention and treatment. National Cancer Institute of Canada
$53,992 2000-02	Pollak M. ATBC cancer risk cohort studies, NIH subcontract from Dr. Albanes
$2,994,444 2000-03	*Pollak M and co-investigators. IGFs and breast cancer: “Streams of Excellence” program award, Canadian Breast Cancer Research Initiative
$418,120 2000-04	Franco E and others including Pollak M. Biomarkers of cervical cancer. CIHR
~$125,000 2000-04	Ziegler R and others including Pollak M. Biomarker of colon cancer risk in the PLCO cohort. National Cancer Institute (USA)
$1,500,000 2000-05	Eyssen G, and others including Pollak M. Canadian Cancer Etiology Research Network, NCIC. (Dr. Pollak leads the “hormonal risk factor” component of the network.)
$3,098,278 2001-07	Bristow R, and others including Pollak M. Canadian Molecular and Micronutrient Prostate Cancer Research Network
$410,000 2003-06	* Pollak M. Silibinin in prostate cancer chemoprevention and treatment. Department of Defense – U.S. Army
$440,000 2003-06	*Pollak M. Co-targeting of IGF-IR signaling and other tyrosine kinases in breast cancer. The Susan G. Komen Breast Cancer Foundation.
$49,000 2003-04	*Pollak M, Majeed N. Model development: IGF-I deficiency and prostate cancer. National Cancer Institute of Canada – Canadian Prostate Cancer Research Initiative
$130,000 2003-05	* Pollak M. Silibinin in prostate cancer chemoprevention and treatment. National Institutes of Health –National Cancer Institute
~$3,000,000 2003-09	Kaplan R, and others including Pollak M and co-investigators. Epidemiology of IGF and cardiovascular events. National Institute of Health
~$2,000,000 2003-06	Kristal AR, and others including Pollak M and co-investigators. Cohort Study of Risks for Benign Prostatic Hyperplasia. National Institute of Health
$141,000 2004-05	Pollak M. Subcontract for laboratory work awarded to MP by John Hopkins University (Using NIH funding)
$130,000 2004-05	Pollak M. Subcontract for laboratory work awarded to MP by NCI intramural program (USA) (Using NIH funding)
$58,500 2005-06	* Pollak M. Relationship between hedgehog signaling and IGF physiology in prostate cancer. (PCRFC)
$2,948,563 2005-09	* Pollak M and co-investigators from University of British Columbia, University of Toronto, Laval University, and McGill University. IGF and insulin signaling pathways in breast cancer: “Translation Acceleration Grant” program award. Canadians Breast Cancer Research Alliance. (MP chairs this multi-center Program.)
~$18,000,000 2005-09	*Lippman S, and others including Pollak M and co-investigators. Biology of the prostate cancer prevention trial. National Cancer Institute (USA)
$50,000.00 2005-09	McTiernan A and others including Pollak M and co-investigators. Glycemic load and obesity effects on cancer biomarkers. National cancer Institute
$375,000 2007-10	*Pollak M. Dietary factors influencing IGF signaling in prostate cancer – laboratory studies (ranked # 1 by review panel) NCIC
$88,000 2007	*Pollak M. Mediators of the adverse impact of obesity on risk for high grade prostate cancer. Prostate Cancer Foundation (Los Angeles)
$1,500,000 2008-11	*Smith MR, and others including Pollak M and co-investigators. Prevention of treatment and disease-related morbidity during androgen deprivation therapy: a multicenter proposal. Prostate Cancer Foundation (Los Angeles)
$1,010,000 2008-10	*Pollak M and co-investigators from McGill University. Clinical targeting of IGF-1/Insulin Signaling via the P13K/AKT/mTOR pathway to treat breast and prostate cancers. Terry Fox Research Institute
$40,000 2009-10	*Pollak M. Influence of Excess Energy Intake on Breast Cancer Behavior. The Weekend to End Breast Cancer and the Jewish General Hospital Foundation
$30,000 2009	Yehiel Zick and *Pollak M. Insulin and IGF-I signaling in cancer. Weizmann-McGill 2009 partnership grants
~$500,000 2009-12	*Pollak M and Harvard collaborators. Modifiable dietary determinants of levels of IGF-I, insulin, and risk of colorectal cancer and lethal prostate cancer. Canadian Cancer Society
$60,000 2009-10	*Pollak M. PTEN loss and energy metabolism in prostate cancer. Prostate Cancer Canada
$10,000 2009	*Pollak M. China – Canada collaboration program, CIHR, seed funds awarded on acceptance of LOI, to allow preparation of a major application.
~$2,300,000 2009-11	*Aviv A and others, including Pollak M and co-investigators. Leukocyte telomere dynamics, gender, menopause, insulin resistance and survival. NIH – National Institute on Aging
$650,000 2010-13	*Pollak M. Research concerning insulin-like growth factors and cancer. Pfizer Canada
$400,000 2010-12	*Pollak M. Murine models to study the effects of diabetes and diabetes treatments, including insulin analogues, on cancer behavior. Novo Nordisk
$195,000 2011-13	*Pollak M. Effects of metformin on colorectal epithelial cell proliferation. Canadian Cancer Society
$115,000 2011-13	*Pollak M. Influence of insulin on androgen production. Prostate Canada Cancer
$1,300,000 2011-14	*Tremblay M and others, including Pollak M. The Terry Fox New Frontiers Program Project on Defining and Applying “Oncometabolism”. CIHR
$2,774,097 2011-16	*Siemiatycki, J. *Pollak, M, and others. Assessing occupational exposures in cancer case-control studies and application to cancers of lung, brain, ovary, and colon. Cancer Research Society
$600,000 2012-2013	*Pollak M. Murine models to study the effects of diabetes and diabetes treatments, including insulin analogues, on cancer behavior (admendment). Novo Nordisk

(B) Clinical Trials

$100,000 1990-93	Principal Investigator for SMS 201-995/CV 205-502 breast cancer trial. Sandoz Canada
$120,000 1993	Principal Investigator for 3 phase II somatostatin trials (colon, ER negative breast, and ER positive breast) Sandoz Canada
See section A	Principal Investigator, NCIC octreotide-tamoxifen breast cancer adjuvant trial. This is a ~800 patient multicenter trial proposed, designed and implemented by Dr. Pollak with involvement of Sandoz (now Novartis) affiliates in Canada and USA as well as head office in Basle, National Cancer Institute of Canada, Medical Research Council of Canada, and more than 25 hospitals across Canada. Funding award for translational research component by MRC-PMAC program (administered by Medical Research Council, Canada), 1996-1999. My lab manages the translational research component of this study, and conducts assays on serum and neoplastic tissue from participating patients.
$50,000 1995	Principal Investigator at McGill for Recombinant humanized anti-HER2 antibody therapy in breast cancer patients with HER2 overexpression. Genentech
$55,000 1995	Principal Investigator at McGill for Randomized double-blind trial to compare efficacy and safety of anastrozole with tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. Zeneca Pharma
$30,000 1996	Principal Investigator at McGill for Phase II study of EM-800 in tamoxifen-resistant breast cancer. CHUL research Center
$60,000 1998	NSABP B29 breast cancer adjuvant trial. Proposed this trial to NSABP, and participated in protocol design.
$40,000 1998-99	Principal Investigator at McGill for phase II study of MDR modifiers. Vertex Pharmaceuticals
$50,000 1998-99	Principal Investigator at McGill phase III study for EM-800 vs. aromatase inhibitors. Scherring
~$100,000 2004-	Principal Investigator at McGill of LBQ707A-2102 Phase Ib Study. Novartis.
~$80,000 2005-	Co-Principal Investigator at McGill of IGF-I receptor blocking antibody Phase Ib study. Pfizer
~$500,000 2004-09	Fleshner N. (PI), Pollak M and co-investigators.Translation Companion Study to PRP.1 Ontario Cancer Research Network
$175,000 2007-11	Pollak M (PI) et al. A pharmacodynamic study of IGF-I receptor blockade in prostate cancer. Pfizer Canada 2007
$80,000 2007-11	Pollak (PI) Laboratory services contract to process specimens from an international breast cancer trial. Pfizer Global (USA)

(C) Grants awarded to trainees during or following study in laboratory of Dr. Pollak

Huynh H. Canadian Breast Cancer Foundation Award	$30,000	1995-96
Nickerson T. FRSQ Studentship	$12,000	1996-97
Huynh H. Cancer Research Society operating grant	$45,000	1996-97
Huynh H. US Army Breast Cancer Program	~$350,000	1997-99
Levitt R. US Army Pre-Doctoral Traineeship	~$67,000	2003-05
Mireuta M. WEBC Studentship Award	$24,000	2007-09
Algire C. MCETC/ FRSQ/ CIHR Studentship Award	$24,000	2008-10
Dool C. MCETC/ FRSQ/ CIHR Studentship Award	$24,000	2008-10
Mashhedi H. MICRTP Studentship Award	$12,000	2010-11
Algire C. CIHR Doctoral Award	$35,000	2010-13

EXAMPLES OF ACADEMIC COLLABORATIONS OUTSIDE McGILL

Dr. Wes Beamer, Jackson Laboratory (“lit” mutation)

Dr. Catharina Larsson, Karolinska Institute, Stockholm (MDGI gene)

Dr. Steven Narod, Chair, Breast Cancer Research, University of Toronto (hormonal modifiers of penetrance of genetic risk factors for cancer)

Dr. Robert Bell, University of Toronto (IGFs and osteosarcoma)

Dr. W Willett, Chair, Dept. of Nutrition, Harvard School of Public Health (Nurses’ Health Study: markers of breast cancer risk)

Dr. R Ziegler, Division of Cancer Genetics and Epidemiology, NCI-NIH, USA (Breast cancer: genetic polymorphisms underlying hormonal risk factors)

Dr. M Stampfer, Harvard University (risk factors for prostate and colon cancer)

Dr. M Gleave, University of British Columbia (novel molecular target identification for prostate and breast cancers)

Dr. R Kaplan, Albert Einstein University (IGFs and cardiovascular disease)

Dr. J Brisson, Laval University (hormonal influences on mammographic breast density)

EXAMPLES OF INDUSTRIAL COLLABORATIONS

AND PRIVATE SECTOR CONSULTING

Novartis Research Institute, Basle, Switzerland

Astra Zeneca Pharmaceuticals, Manchester, UK

Diagnostic Systems Limited, Webster, Texas (appointed to Scientific Advisory Board, 1998)

Orion-Farmos, Helsinki, Finland

Ipsen Biotech, Paris, France

Sensus Biotech, Austin, Texas

L.A.B. Pharma Research International, Vaudreuil, Quebec

Cadus Pharmaceuticals, NY

Axys Pharma, San Francisco

Sanofi-Aventis, Paris

Pfizer Global Research, New York

Boerringer-Ingleheim, Vienna

Bristol-Myers Squibb, New Jersey

PATENTS

- Bispecific oligonucleotide for the treatment of CNS malignancies (co-inventor, patent owned by University of British Columbia)

- IGF-I and related analytes in assessing cancer risk (co-inventor, patent licensed to Diagnostic Systems Limited)

PUBLICATIONS

(* indicates first author supervised by Dr. M Pollak)

Peer-reviewed articles (published or in press)

1978-1989

1. Fletcher S, Ratzer G, Pollak M. Computer-based appointment scheduling for ambulatory patients. Meth Information Med 17: 167-72, 1978.

2. Pollak MN. Computer-aided information management systems in clinical trials. A physician’s perspective. Comput Programs Biomed 16: 243-51, 1983.

3. Buick RN, Pollak MN. Perspectives on clonogenic tumor cells, stem cells, and oncogenes. Cancer Res 44: 4909-18, 1984. Times cited (as of 2011): 124

4. Filmus J, Pollak MN, Cailleau R, Buick RN. MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem Biophys Res Commun 128: 898-905, 1985. Times cited (as of 2011): 264

5. Filmus J, Pollak MN, Cairncross JG, Buick RN. Amplified, overexpressed and rearranged epidermal growth factor receptor gene in a human astrocytoma cell line. Biochem Biophys Res Commun 131: 207-15, 1985. Times cited (as of 2011): 82

6. Filmus J, Trent JM, Pollak MN, Buick RN. Epidermal growth factor receptor gene-amplified MDA-468 breast cancer cell line and its nonamplified variants. Mol Cell Biol 7: 251-7, 1987. Times cited (as of 2011): 108

7. Pollak MN, Perdue JF, Margolese RG, Baer K, Richard M. Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Lett 38: 223-30, 1987. Times cited (as of 2011): 111

8. Pollak MN, Polychronakos C, Yousefi S, Richard M. Characterization of insulin-like growth factor I (IGF-I) receptors of human breast cancer cells. Biochem Biophys Res Commun 154: 326-31, 1988. Times cited (as of 2011): 67

9. *Gonzalez-Vela JL, Panasci L, Black M, Pollak M, Margolese R. Combination chemotherapy with carboplatinum and bleomycin for advanced and recurrent head and neck cancer: a phase II study. J Surg Oncol 39: 215-6, 1988.

10. Suissa S, Pollak M, Spitzer WO, Margolese R. Body size and breast cancer prognosis: a statistical explanation of the discrepancies. Cancer Res 49: 3113-6, 1989. Times cited (as of 2011): 31

11. Pollak MN, Polychronakos C, Guyda H. Somatostatin analogue SMS 201-995 reduces serum IGF-1 levels in patients with neoplasms potentially dependent on IGF-1. Anticancer Res 9: 889-91, 1989. Times cited (as of 2011): 96

1990

12. Pollak M, Richard M. Suramin blockade of insulin-like growth factor I- stimulated proliferation of human osteosarcoma cells. J Natl Cancer Inst 82: 1349-52, 1990. Times cited (as of 2011): 170

13. Pollak MN, Polychronakos C, Richard M. Insulin-like growth factor 1: a potent mitogen for human osteogenic sarcoma. J Natl Cancer Inst 82: 301-5, 1990. Times cited (as of 2011): 83

14. Panasci L, Shenouda G, Begin L, Pollak M, Reinke A, Margolese R. Mitomycin C and mitoxantrone chemotherapy for advanced breast cancer: efficacy with minimal gastrointestinal toxicity and alopecia. Cancer Chemother Pharmacol 26: 457-60, 1990.

15. Pollak M, Costantino J, Polychronakos C, Blauer SA, Guyda H, Redmond C, Fisher B, Margolese R. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 82: 1693-7, 1990. [see also favorable editorial comment: J Natl Cancer Inst 82: 1662-3, 1990]. Times cited (as of 2011): 234

1991

16. Dawson NA, Costanza ME, Korzun AH, Clamon GH, Pollak M, Vogelzang NJ, Carey RW, Norton L. Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study. Med Pediatr Oncol 19: 283-8, 1991. Times cited (as of 2011): 12

17. Pollak M, Boyarsky A, Gora P. A mathematical model describing consequences of abnormally high levels of epidermal growth factor receptor on the proliferation of neoplastic cells. Cancer Invest 9: 513-20, 1991.

18. *Yao XJ, Wainberg MA, Richard M, Pollak M. The ability of suramin to block CD4-gp120 binding is reversed in the presence of albumin. Antimicrob Agents Chemother 35: 2636-8, 1991.

19. *Yao XJ, Wainberg MA, Pollak M. The inhibitory effects of suramin on HIV-1 are attenuated in the presence of albumin. AIDS 5: 1389-91, 1991.

1992

20. *Malaab SA, Pollak MN, Goodyer CG. Direct effects of tamoxifen on growth hormone secretion by pituitary cells in vitro. Eur J Cancer 28A: 788-93, 1992. Times cited (as of 2011): 33

21. Tannenbaum G, Gurd W, Lapointe M, Pollak M. Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. Endocrinology 130: 3395-401, 1992. Times cited (as of 2011): 59

22. Pollak M, Sem A, Richard M, Tetenes E, Bell R. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J Natl Cancer Inst 84: 966-71, 1992. Times cited (as of 2011): 59

23. Pollak MN, Huynh HT, Lefebvre SP. Tamoxifen reduces serum-like growth factor I (IGF-I). Breast Cancer Res Treat 22: 91-100, 1992. Times cited (as of 2011): 81

24. Pollak M, Galant K, Poisson R, Harris A. Potential role for somatostatin analogues in breast cancer: rationale and description of an ongoing trial. Metabolism 41: 9 Suppl 2, 119-20, 1992.

1993

25. *Friedl A, Jordan VC, Pollak M. Suppression of serum insulin-like growth factor-I levels in breast cancer patients during adjuvant tamoxifen therapy. Eur J Cancer 29A: 1368-72, 1993. Times cited (as of 2011): 46

26. *Huynh H, Tetenes E, Wallace L, Pollak M. In vivo inhibition of insulin-like growth factor 1 gene expression by tamoxifen. Cancer Res 53: 1727-30, 1993. Times cited (as of 2011): 125

27. Pollack R, Pollak M, Rochon L. Pregnancy complicated by medulloblastoma with metastases to the placenta. Obstet Gynecol 81: 858-9, 1993.

28. *Pratt SE, Pollak MN. Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res 53: 5193-8, 1993. Times cited (as of 2011): 94

29. Tonin P, Ehrenborg E, Lenoir G, Feunteun J, Lynch H, Morgan K, Zazzi H, Vivier A, Pollak M, Huynh H, et al. The human insulin-like growth factor- binding protein 4 gene maps to chromosome region 17q12-q21.1 and is close to the gene for hereditary breast-ovarian cancer. Genomics 18: 414-7, 1993. Times cited (as of 2011): 15

30. *Huynh H, Pollak M. Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. Cancer Res 53: 5585-8, 1993. Times cited (as of 2011): 81

1994

31. *Pratt SE, Pollak MN. Insulin-like growth factor binding protein 3 (IGF-BP3) inhibits estrogen-stimulated breast cancer cell proliferation. Biochem Biophys Res Commun 198: 292-7, 1994. Times cited (as of 2011): 64

32. *Sekyi-Otu A, Bell R, Andrulis I, Pollak M. Metastatic behavior of the RIF-1 murine fibrosarcoma: inhibited by hypophysectomy and partially restored by growth hormone replacement. J Natl Cancer Inst 86: 628-32, 1994.

33. *Huynh H, Pollak M. Uterotrophic actions of estradiol and tamoxifen are associated with inhibition of uterine insulin-like growth factor binding protein 3 gene expression. Cancer Res 54: 3115-9, 1994. Times cited (as of 2011): 47

34. *Huynh H, Pollak M. Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue. Biochem Biophys Res Commun 203: 253-9, 1994. Times cited (as of 2011): 44

35. Weckbecker G, Tolcsvai L, Stolz B, Pollak M, Bruns C. Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz (alpha) anthracene-induced rat mammary carcinomas. Cancer Res 54: 6334-7, 1994. [A footnote identifies Dr. Pollak and Dr. Bruns as co-senior authors who contributed equally to this work.] Times cited (as of 2011): 73

1995

36. *Huynh H, Pollak M. HH2A, an immortalized bovine breast epithelial cell line, expresses the gene encoding mammary derived growth inhibitor. In Vitro Cell Dev Biol Anim 31: 25-9, 1995.

37. Rosenberg L, Barkun A, Denis MH, Pollak M. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer 75: 23-8, 1995. Times cited (as of 2011): 47

38. *Sekyi-Otu A, Bell RS, Ohashi C, Pollak M, Andrulis IL. Insulin-like growth factor I (IGF-I) receptors, IGF-I, and IGF-2 are expressed in primary human sarcomas. Cancer Res 55: 129-34, 1995. Times cited (as of 2011): 42

39. Bloom C, Lisbona A, Begin LR, Pollak M. Extraosseous Ewing's sarcoma. Can Assoc Radiol J 46: 131-3, 1995.

40. *Huynh HT, Larsson C, Narod S, Pollak M. Tumor suppressor activity of the gene encoding mammary-derived growth inhibitor. Cancer Res 55: 2225-31, 1995. Times cited (as of 2011): 81

41. Montaner J, Harris A, Amar J, Fanning M, and multicenter study group (including Pollak M). Octreotide therapy in AIDS-related refractory diarrhea: results of a multicenter Canadian-European study. AIDS 9: 209-10, 1995.

42. *Huynh H, Pollak M. Regulation of IGFBP-3 expression in breast cancer cells and uterus by estradiol and antiestrogens: correlations with effects on proliferation: a review. Prog Growth Factor Res 6: 495-501, 1995.

1996

43. *Yang XF, Beamer WG, Huynh H, Pollak M. Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. Cancer Res 56: 1509-11, 1996.

44. *Phelan C, Larsson C, Baird S, Futreal A, Ruttledge M, Morgan K, Tonin P, Huynh H, Korneluk R, Pollak M, Narod S. The human mammary-derived growth inhibitor (MDGI) gene: genomic structure and mutation analysis in human breast tumors. Genomics 34: 63-8, 1996. [Dr. Pollak and Dr. Narod are co-senior authors who contributed equally to this work] Times cited (as of 2011): 29

45. *Huynh H, Alpert L, Pollak M. Silencing of the mammary-derived growth inhibitor (MDGI) gene in breast neoplasms is associated with epigenetic changes. Cancer Res 56: 4865-70, 1996. Times cited (as of 2011): 52

46. *Huynh H, Yang X, Pollak M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 271: 1016-21, 1996. Times cited (as of 2011): 178

47. Pollak M. Peptide growth factors and breast cancer treatment: recent translational research. Recent Results Cancer Res 140: 43-9, 1996.

48. Pollak M. Enhancement of the anti-neoplastic effects of tamoxifen by somatostatin analogues. Digestion 57: 29-33, 1996. Times cited (as of 2011): 13

49. *Huynh H, Alpert L, Pollak M. Pregnancy-dependent growth of mammary tumors is associated with overexpression of insulin-like growth factor II. Cancer Res 56: 3651-4, 1996. Times cited (as of 2011): 13

50. *Huynh H, Yang XF, Pollak M. A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780. Cell Growth Differ 7: 1501-6, 1996. Times cited (as of 2011): 61

51. *Huynh H, Nickerson T, Pollak M, Yang X. Regulation of IGF-I receptor expression by the pure antiestrogen ICI 182780. Clin Cancer Res 2: 2037-42, 1996. Times cited (as of 2011): 66

1997

52. *Rozen F, Yang X, Huynh H, Pollak M. Antiproliferative action of vitamin D-related compounds and insulin-like growth factor binding protein 5 accumulation. J Natl Cancer Inst 89: 652-6, 1997. Times cited (as of 2011): 70

53. Karp SE, Tonin PN, Begin LR, Martinez JJ, Zhang JC, Pollak MN, Foulkes WD. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 80: 435-41, 1997. Times cited (as of 2011): 125

54. *Nickerson T, Huynh H, Pollak M. IGFBP-3 induces apoptosis in MCF7 breast cancer cells. Biochem Biophys Res Commun 237: 690-3, 1997. Times cited (as of 2011): 110

55. *Huynh H, Pollak M. Stabilization of mammary-derived growth inhibitor messenger RNA by antiestrogens. Clin Cancer Res 3: 2151-6, 1997.

56. Foulkes WD, Wong N, Brunet JS, Begin LR, Zhang JC, Martinez JJ, Rozen F, Tonin PN, Narod SA, Karp SE, Pollak MN. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res 3: 2465-9, 1997. Times cited (as of 2011): 83

57. *Huynh H, Beamer W, Pollak M. Overexpression of IGFBP-4 by MCF-7 breast cancer cells is associated with reduced responsiveness to IGFs in vitro and reduced tumor growth in vivo. Int J Oncol 11: 193-7, 1997.

58. Pollak M. The potential role of somatostatin analogues in breast cancer treatment. Yale J Biol Med 70: 535-9, 1997.

1998

59. *Nickerson T, Pollak M, Huynh H. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding IGF binding proteins 2, 3, 4, and 5. Endocrinology 139: 807-10, 1998. Times cited (as of 2011): 100

60. Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc for Exp Biol Med 217: 143-52, 1998. Times cited (as of 2011): 159

61. *Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-6, 1998. [see also favorable editorial comment – Science 279: 475, 1998] Times cited (as of 2011): 1,271

62. Pollak MN. Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res. Treat 47: 209-17, 1998. Times cited (as of 2011): 75

63. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. Circulating concentrations of insulin-like growth factor I and risk of breast cancer. Lancet 351: 1393-6, 1998. [see also favorable editorial comment: Lancet 351: 1373-4, 1998] Times cited (as of 2011): 1,090

64. Pollak M. Effects of anti-estrogens on insulin-like growth factor-I physiology systemically and in the uterus. Eur J Cancer 34: (Supp 4) S1-S8, 1998.

65. *Huynh H, Pollak M, Zhang JC. Regulation of IGF-II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 and its analog EB1089. Int J Oncol 13: 137-43, 1998. Times cited (as of 2011): 67

66. *Rozen F, Zhang J, Pollak M. Antiproliferative action of tumor necrosis factor-alpha on MCF-7 breast cancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation. Int J Oncol 13: 865-9, 1998. Times cited (as of 2011): 64

67. *Burrow S, Andrulis IL, Pollak M, Bell RS. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol 69: 21-7, 1998. Times cited (as of 2011): 48

1999

68. Ingle JN, Suman VJ, Kardinal CG, Krook JE, Mailliard JA, Veeder MH, Loprinzi CL, Dalton RJ, Hartmann LC, Conover CA, Pollak MN. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 85: 1284-92, 1999. Times cited (as of 2011): 52

69. *Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein 3. J Natl Cancer Inst 91: 620-5, 1999. [see also favorable editorial comment- J Natl Cancer Inst 91: 579-81, 1999] Times cited (as of 2011): 643

70. Pollak M, Beamer W, Zhang JC. Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 17: 383-90, 1998-1999. Times cited (as of 2011): 102

71. Pollak M. IGF-I physiology and breast cancer. Recent Results Cancer Res 152: 63-70, 1998. Times cited (as of 2011): 19

72. Rosen C, Pollak M. Circulating IGF-I: New Perspective for a New Century. Trends Endocrinol Metab 10: 136-141, 1999. Times cited (as of 2011): 95

73. *Nickerson T, Zhang J, Pollak M. Regression of DMBA-induced breast carcinoma following ovariectomy is associated with increased expression of genes encoding insulin-like growth factor binding proteins. Int J Oncol 14: 987-90, 1999.

74. *Nickerson T, Miyake H, Gleave M, Pollak M. Castration-induced apoptosis of androgen-dependent shinogi carcinoma is associated with increased expression of genes encoding IGF-binding proteins. Cancer Res 59: 3392-5, 1999. Times cited (as of 2011): 52

75. *Rozen F, Pollak M. Inhibition of insulin-like growth factor 1 receptor signaling by the vitamin D analogue EB1089 in MCF-7 breast cancer cells: A role for insulin-like growth factor binding proteins. Int J Oncol 15: 589-94, 1999. Times cited (as of 2011): 26

76. Buhlmann C, Borchers T, Pollak M, Spener F. Fatty acid metabolism in human breast cancer cells (MCF7) transfected with heart-type fatty acid binding protein. Mol Cell Biochem 199: 41-8, 1999. Times cited (as of 2011): 15

77. *Nickerson T, Pollak M. Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins. Urology 54: 1120-5, 1999. Times cited (as of 2011): 29

78. Platz EA, Pollak MN, Rimm EB, Majeed N, Tao Y, Willett WC, Giovannucci E. Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol Biomarkers Prev 8: 1107-10, 1999. Times cited (as of 2011): 75

2000

79. Huynh H, Beamer W, Pollak M, Chan TW. Modulation of transforming growth factor beta1 gene expression in the mammary gland by insulin-like growth factor I and octreotide. Int J Oncol 16: 277-81, 2000.

80. Miyake H, Pollak M, Gleave ME. Castration-induced up-regulation of IGFBP-5 potentiates IGF-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res 60: 3058-64, 2000. Times cited (as of 2011): 87

81. Foulkes WD, Chappuis PO, Wong N, Brunet JS, Vesprini D, Rozen F, Yuan ZQ, Pollak MN, Kuperstein G, Narod SA, Begin LR. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol 3: 307-13, 2000. Times cited (as of 2011): 44

82. Giovannucci E, Pollak MN, Platz EA, Willett WC, Stampfer MJ, Majeed N, Colditz GA, Speizer FE, Hankinson SE. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 9: 345-9, 2000. Times cited (as of 2011): 248

83. Pollak M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer 36: 1224-8, 2000. Times cited (as of 2011): 203

84. Platz EA, Pollak MN, Willett WC, Giovannucci E. Vertex balding, plasma insulin-like growth factor 1, and insulin-like growth factor binding protein 3. J Am Acad Dermatol 42: 1003-7, 2000.

85. Wilkin F, Paquette J, Ledru E, Mamelin C, Pollak M, Deal CL. H19 sense and antisense transgenes modify insulin-like growth factor-II mRNA levels. Eur J Biochem 267: 4020-7, 2000. Times cited (as of 2011): 22

86. Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE. Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic Density. Cancer Res 60: 3744-8, 2000. Times cited (as of 2011): 161

87. * Zi X, Zhang J, Agarwal R, Pollak M. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res 60: 5617-20, 2000. Times cited (as of 2011): 88

88. Pollak M. The question of a link between insulin-like growth factor physiology and neoplasia. Growth Horm IGF Res 10 Suppl B: 21-4, 2000.

89. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 18: 3758-67, 2000. Times cited (as of 2011): 524

2001

90. Jernstrom H, Deal C, Wilkin F, Chu W, Tao Y, Majeed N, Hudson T, Narod SA, Pollak M. Genetic and non-genetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 10: 377-84, 2001. Times cited (as of 2011): 101

91. Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, Hudson T, Stampfer M, Pollak M. Novel promoter polymorphism in IGFBP3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 86: 1274-80, 2001. Times cited (as of 2011): 123

92. Jernstrom H, Chu W, Vesprini D, Tao Y, Majeed N, Deal C, Pollak M, Narod SA. Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. Mol Genet Metab 72: 144-54, 2001. Times cited (as of 2011): 71

93. Trojan DA, Collet J, Pollak MN, Shapiro S, Jubelt B, Miller RG, Agre JC, Munsat TL, Hollander D, Tandan R, Robinson A, Finch L, Ducruet T, Cashman NR. Serum insulin-like growth factor-I (IGF-I) does not correlate positively with isometric strength, fatigue, and quality of life in post-polio syndrome. J Neurol Sci 182: 107-15, 2001. Times cited (as of 2011): 13

94. Pollak M. Insulin-like growth factors and prostate cancer. Epidemiol Rev 23: 59-66, 2001. Times cited (as of 2011): 65

95. Chokkalingam AP, McGlynn KA, Gao YT, Pollak M, Deng J, Sesterhenn IA, Mostofi FK, Fraumeni JF Jr, Hsing AW. Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China. Cancer Res 61: 4333-6, 2001. Times cited (as of 2011): 115

96. Tolcher AW, Kennedy A, Padley RJ, Majeed N, Pollak M, Kantoff PW. Other novel agents: Rationale and current status as chemopreventive agents. Urology 57: 86-9, 2001.

97. Pollak M, Blouin M-J, Zhang JC, Kopchick J.J. Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. Br J Cancer 85: 428-30, 2001. Times cited (as of 2011): 64

98. Chokkalingam AP, Pollak M, Fillmore C, Gao YT, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP, Ziegler RG, Fraumeni JF Jr, Hsing AW. Insulin-like growth factors and prostate cancer: a population-based cased-control study in China. Cancer Epidemiol Biomarkers Prev 10: 421-7, 2001. Times cited (as of 2011): 115

99. He B, Deckelbaum RA, Miao D, Lipman ML, Pollak M, Goltzman D, Karaplis AC. Tissue-specific targeting of the pthrp gene: the generation of mice with floxed alleles. Endocrinology 142: 2070-7, 2001. Times cited (as of 2011): 19

100. *Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M. In vivo of LAPC-9 and LNCaP cancer models to androgen independence is associated with increased expression of IGF-I and IGF-IR. Cancer Res 61: 6276-80, 2001. Times cited (as of 2011): 128

101. Thorner M, and writing committee (including Pollak M). Critical evaluation of the safety of recombinant human growth hormone administration: statement from the growth hormone research society. J Clin Endocrin Metab 86: 1868-70, 2001. Times cited (as of 2011): 78

102. Kucuk O, Sarkar FH, Sakr W, Djuric Z, Pollak MN, Khachik Y, Li YW, Banerjee M, Grignon D, Bertram JS, Crissman JD, Pontes EJ, Wood DP Jr. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev 10: 861-8, 2001. Times cited (as of 2011): 191

103. Chan TW, Pollak M, Huynh H. Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780. Clin Cancer Res 7: 2545-54, 2001. Times cited (as of 2011): 36

104. Ma J, Giovannucci E, Pollak M, Chan JM, Gaziano JM, Willett W, Stampfer MJ. Milk intake, circulating levels of insulin like growth factor-I and risk of colorectal cancer in men. J Natl Cancer Inst 93: 1330-6, 2001. Times cited (as of 2011): 86

105. *Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93: 1852-7, 2001. [see also favorable editorial comment- J Natl Cancer Inst 93: 1830-2, 2001]. Times cited (as of 2011): 397

2002

106. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94: 1099-106, 2002. Times cited (as of 2011): 253

107. Giovannucci E, Pollak M. Risk of cancer after growth-hormone treatment. [editorial] Lancet 360: 268-9, 2002. Times cited (as of 2011): 13

108. Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S, Overmoyer B, Garg V, Ette E, Harding MW, Demetri GD. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin Cancer Res 8: 670-8, 2002. Times cited (as of 2011): 46

109. Missmer SA, Haiman CA, Hunter DJ, Willett WC, Colditz GA, Speizer FE, Pollak MN, Hankinson SE. A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer. Int J Cancer 100: 332-6, 2002. Times cited (as of 2011): 64

110. Kucuk O, Sarkar FH, Sakr W, Khachik F, Djuric Z, Banerjee M, Pollak MN, Bertram JS, Wood DP. Lycopene in the treatment of prostate cancer. Pure and Applied Chemistry 74: 1443-50, 2002.

111. Holmes MD, Pollak MN, Willett WC, Hankinson SE. Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein-3 concentrations. Cancer Epidemiol Biomarkers Prev 11: 852-61, 2002. Times cited (as of 2011): 161

112. Holmes MD, Pollak MN, Hankinson SE. Lifestyle correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein-3 concentrations. Cancer Epidemiol Biomarkers Prev 11: 862-7, 2002. Times cited (as of 2011): 88

113. Deitel K, Dantzer D, Ferguson P, Pollak M, Beamer W, Andrulis I, Bell R. Reduced growth of human sarcoma xenografts in hosts homozygous for the lit mutation. J Surg Oncol 81: 75-9, 2002. Times cited (as of 2011): 109

114. Giovannucci E, Haiman CA, Platz EA, Hankinson SE, Pollak MN. Dinucleotide repeat in the insulin-like growth factor-I gene is not related to risk of colorectal adenoma. Cancer Epidemiol Biomarkers Prev 11: 1509-10, 2002.

115. Spitz MR, Barnett MJ, Goodman GE, Thornquist MD, Wu X, Pollak M. Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort. Cancer Epidemiol Biomarkers Prev 11: 1413-8, 2002. Times cited (as of 2011): 44

116. Kucuk O, Sarkar FH, Djuric Z, Sakr W, Pollak MN, Khachik F, Banerjee M, Bertram JS, Wood DP Jr. Effects of lycopene supplementation in patients with localized prostate cancer. Exp Biol Med 227: 881-5, 2002. Times cited (as of 2011): 64

117. *Levitt RJ, Pollak M. Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells. Cancer Res 62: 7372-6, 2002. Times cited (as of 2011): 38

118.             *Camirand A, Lu Y, Pollak M. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit 8: BR521-6, 2002. Times cited (as of 2011): 56

119. Ismail AH, Pollak M, Behlouli H, Tanguay S, Begin LR, Aprikian AG. Insulin-like growth factor-1 and insulin-like growth factor binding protein-3 for prostate cancer detection in patients undergoing prostate biopsy. J Urol 168: 2426-30, 2002. Times cited (as of 2011): 15

2003

120. Giovannucci E, Pollak M, Liu Y, Platz EA, Majeed N, Rimm EB, Willet WC. Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev 12: 84-9, 2003. Times cited (as of 2011): 119

121. Pollak MN, Foulkes W. Challenges to cancer control by screening. Nat Rev Cancer 3: 297-303, 2003. Times cited (as of 2011): 16

122. Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 12: 412-8, 2003. Times cited (as of 2011): 75

123. Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, Albanes D. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res 63: 3991-4, 2003. Times cited (as of 2011): 80

124. Nomura AM, Stemmermann GN, Lee J, Pollak MN. Serum insulin-like growth factor I and subsequent risk of colorectal cancer among Japanese-American men. Am J Epidemiol 158: 424-31, 2003. Times cited (as of 2011): 26

125. Schernhammer ES, Hankinson SE, Hunter DJ, Blouin MJ, Pollak MN. Polymorphic variation at the -202 locus in IGFBP3: Influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. Int J Cancer 107: 60-4, 2003. Times cited (as of 2011): 57

126. Ismail HA, Pollak M, Behlouli H, Tanguay S, Begin LR, Aprikian AG. Serum insulin-like growth factor (IGF) – 1 and IGF-binding protein-3 do not correlate with Gleason score or quantity of prostate cancer in biopsy samples. BJU Int 92: 699-702, 2003.

127. VanHouten JN, Dann P, Stewart AF, Watson CJ, Pollak M, Karaplis AC, Wysolmerski JJ. Mammary-specific deletion of parathyroid hormone-related protein preserves bone mass during lactation. J Clin Invest 112: 1429-36, 2003. Times cited (as of 2011): 32

128. Nam RK, Zhang WW, Trachtenberg J, Jewett MA, Emami M, Vesprinin D, Chu W, Ho M, Sweet J, Evans A, Toi A, Pollak M, Narod SA. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol Biomarkers Prev 12: 1429-37, 2003. Times cited (as of 2011): 43

129. Hussain M, Banerjee M, Sarkar FH, Djuric Z, Pollak MN, Doerge D, Fontana J, Chinni S, Davis J, Forman J, Wood DP, Kucuk O. Soy isoflavones in the treatment of prostate cancer. Nutr Cancer 47: 111-7, 2003. Times cited (as of 2011): 72

2004

130. *Lu Y, Zi X, Pollak M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 108: 334-41, 2004. Times cited (as of 2011): 109

131. *Lu Y, Zi X, Zhao Y, Pollak M. Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells. Biochem Biophys Res Commun 313: 709-15, 2004.

132. Schairer C, Hill D, Fears T, Ziegler R, Hoover R, Pollak M. Serum concentrations of IGF-I, IGFBP-3, and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women. Int J Cancer 108: 773-9, 2004. Times cited (as of 2011): 44

133. *Levitt RJ, Buckley J, Blouin MJ, Schaub B, Triche TJ, Pollak M. Growth inhibiton of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression. Biochem Biophys Res Commun 316: 421-8, 2004. Times cited (as of 2011): 17

134. Labrie F, Champagne P, Labrie C, Roy J, Laverdiere J, Provencher L, Potvin M, Drolet Y, Pollak M, Panasci L, L'Esperance B, Dufresne J, Latreille J, Robert J, Samson B, Jolivet J, Yelle L, Cusan L, Diamond P, Candas B. Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer. J Clin Oncol 22: 864-71, 2004. Times cited (as of 2011): 24

135. Ma J, Giovannucci EL, Pollak MN, Leavitt A, Tao Y, Gaziano JM, Stampfer MJ. A prospective study of plasma c-peptide and colorectal cancer risk in men. J Natl Cancer Inst 96: 546-53, 2004. Times cited (as of 2011): 126

136. Lai JH, Vesprini D, Zhang W, Yaffe MJ, Pollak M, Narod SA. A polymorphic locus in the promoter region of the IGFBP3 gene is related to mammographic breast density. Cancer Epidemiol Biomarkers Prev 13: 573-82, 2004. Times cited (as of 2011): 41

137. Stolzenberg-Solomon RZ, Limburg P, Pollak M, Taylor PR, Virtamo J, Albanes D. Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers. Cancer Epidemiol Biomarkers Prev 13: 438-44, 2004. Times cited (as of 2011): 17

138. *Camirand A, Pollak M. Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells. Br J Cancer 90: 1825-9, 2004. Times cited (as of 2011): 27

139. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Solicited Review. Nature Rev Cancer 4: 505-18, 2004. Times cited (as of 2011): 523

2005

140. Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L. Randomized phase II study of two dose of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trial Group. J Clin Oncol 23: 455-60, 2005. Times cited (as of 2011): 97

141. *Schernhammer ES, Holly JM, Pollak MN, Hankinson SE. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 3: 699-704, 2005. Times cited (as of 2011): 73

142. Kristal AR, King IB, Albanes D, Pollak MN, Stanzyk FZ, Santella RM, Hoque A. Centralized blood precessing for the selenium and vitamin E cancer prevention trial: effects of delayed processing on caroteniods, tocopherols, insulin-like growth factor-I, insulin-like growth factor binding protein 3, steroid hormones, and lymphocyte viability. Cancer Epidemiol Biomarkers Prev 14: 727-30, 2005. Times cited (as of 2011): 15

143. Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE, Giovannucci E. A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 14: 850-5, 2005. Times cited (as of 2011): 89

144. Nam RK, Trachtenberg J, Jewitt MA, Toi A, Evans A, Narod SA, Pollak M. Serum insulin-like growth factor-1 (IGF-1) levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-1 physiology and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 14: 1270-3, 2005.

145. Diorio C, Pollak M, Byrne C, Masse B, Hebert-Croteau N, Yaffe M, Cote G, Berube S, Morin C, Brisson J. Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Biomarkers Prev 14: 1065-73, 2005. Times cited (as of 2011): 63

146. Meyerhardt JA, Sloan JA, Sargent DJ, Goldberg RM, Pollak M, Morton RF, Ramanathan RK, Williamson SK, Findlay BP, Fuchs CS. Associations between plasma insulin-like gowth factor proteins and c-peptide and quality of life in patients with metastatic colorectal cancer. Cancer Epidemiol Biomarkers Prev 14: 1402-10, 2005.

147. Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes and Control 16: 255-62, 2005. Times cited (as of 2011): 31

148. Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, Yorida E, Turbin D, Dedhar S, Nelson C, Pollak M, Leighton Grimes H, Miller K, Badve S, Huntsman D, Blake-Gilks C, Chen M, Pallen CJ, Dunn SE. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 24: 4281-92, 2005. Times cited (as of 2011): 74

149. *Camirand A, Zakikhani M, Young F, Pollak M. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res 7: R570-9, 2005. Times cited (as of 2011): 52

150. *Majeed N, Blouin MJ, Kaplan-Lefko PJ, Barry-Shaw J, Greenberg NM, Gaudreau P, Bismar TA, Pollak M. A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Oncogene 24: 4736-40, 2005. Times cited (as of 2011): 25

151. Berube S, Diorio C, Masse B, Herbert-Croteau N, Byrne C, Cote G, Pollak M, Yaffe M, Brisson J. Vitamin D and calcium intakes from food or supplements and mammographic breast density. Cancer Epidemiol Biomarkers Prev 14: 1553-9, 2005. Times cited (as of 2011): 40

152. Pinheiro SP, Holmes MD, Pollak MN, Barieri RL, Hankinson SE. Racial differences in premenopausal endogenous hormones. Cancer Epidemiol Biomarkers Prev 14: 2147-53, 2005. Times cited (as of 2011): 29

153. Kucab JE, Lee C, Chen CS, Zhu J, Gilks CB, Cheang M, Huntsman D, Yorida E, Emerman J, Pollak M, Dunn SE. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res 7: R796-807, 2005. Times cited (as of 2011): 39

154. *Levitt RJ, Georgescu MM, Pollak M. PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2. Biochem Biophys Res Commun 336: 1056-61, 2005. Times cited (as of 2011): 24

155. Diorio C, Pollak M, Byrne C, Masse B, Hebert-Croteau N, Yaffe M, Cote G, Berube S, Brisson J. Levels of C-peptide and mammographic breast density. Cancer Epidemiol Biomarkers Prev 14: 2661-4. 2005.

2006

156. Diorio C, Berube S, Byrne C, Masse B, Hebert-Croteau N, Yaffe M, Cote G, Pollak M, Brisson J. Influence of insulin-like growth factors on the strength of the relation of vitamin D and calcium intakes to mammographic breast density. Cancer Res 66: 588-97, 2006. Times cited (as of 2011): 17

157. Rollison DE, Newschaffer CJ, Tao Y, Pollak M, Helzlsouer KJ. Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer. Int J Cancer 118: 1279-84, 2006. Times cited (as of 2011): 20

158. Rousseau MC, Parent ME, Pollak MN, Siemiatycki J. Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. Int J Cancer 118: 2105-9, 2006. Times cited (as of 2011): 50

159. Gotlieb WH, Bruchim I, Gu J, Shi Y, Camirand A, Blouin MJ, Zhao Y, Pollak MN. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. Gynecol Oncol 100: 389-96, 2006. Times cited (as of 2011): 32

160. Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE, Giovannucci E. C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women. Cancer Epidemiol Biomarkers Prev 15: 750-5, 2006. Times cited (as of 2011): 31

161. Harris TG, Strickler HD, Yu H, Pollak MN, Monrad ES, Travin MI, Xue X, Rohan TE, Kaplan RC. Specimen processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding protein-3. Growth Horm IGF Res 16: 86-92, 2006.

162. Missmer SA, Spiegelman D, Bertone-Johnson ER, Barbieri RL, Pollak MN, Hankinson SE. Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiol Biomarkers Prev 15: 972-8, 2006. Times cited (as of 2011): 49

163. Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 13: 583-92, 2006. Times cited (as of 2011): 66

164. Tseng PH, Weng SC, Wang YC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived PDK-1 inhibitor. Mol Pharmacol 70: 1534-41, 2006. Times cited (as of 2011): 21

165. *Zakikhani M, Dowling R, Fantus GI, Sonenberg N, Pollak M. Metformin is an AMP-kinase dependent growth inhibitor for breast cancer cells. Cancer Res 66: 10269-73, 2006. Times cited (as of 2011): 181

166. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, Lippman SM, Platz EA, Pollak MN, Thompson IM, Kristal AR. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Epidemiol Biomarkers Prev 15: 1977-83, 2006. Times cited (as of 2011): 96

167. Ahn J, Weinstein SJ, Snyder K, Pollak MN, Virtamo J, Albanes D. No association between serum insulin-like growth factor (IGF)-I, IGF-binding protein-3, and lung cancer risk. Cancer Epidemiol Biomarkers Prev 15: 2010-2, 2006.

168. Tran CD, Diorio C, Berube S, Pollak M, Brisson J. Relation of insulin-like growth factor (IGF) I and IGF-binding protein 3 concentrations with intakes of fruit, vegetables, and antioxidants. Am J Clin Nutr 84: 1518-26, 2006.

2007

169. Liu B, Lee KW, Anzo M, Zhang B, Zi X, Tao Y, Shiry L, Pollak M, Lin S, Cohen P. Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene 26: 1811-9, 2007. Times cited (as of 2011): 25

170. Okereke O, Kang JH, Ma J, Hankinson SE, Pollak MN, Grodstein F. Plasma IGF-I levels and cognitive performance in older women. Neurobiol Aging 28: 135-42, 2007.

171. Eliassen AH, Tworoger SS, Mantzoros CS, Pollak MN, Hankinson SE. Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women. Cancer Epidemiol Biomarkers Prev 16: 161-4, 2007. Times cited (as of 2011): 16

172. Pollak M. Insulin-like growth factor-related signaling and cancer development. Recent Results Cancer Res 174: 49-53, 2007. Times cited (as of 2011): 27

173. Tamimi RM, Cox DG, Kraft P, Pollak MN, Haiman CA, Cheng I, Freedman ML, Hankinson SE, Hunter DJ, Colditz GA. Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study. Br Cancer Res 9: R18, 2007. Times cited (as of 2011): 34

174. Kaplan RC, McGinn AP, Pollak MN, Kuller LH, Strickler HD, Rohan TE, Cappola AR, Xue X, Psaty BM. Association of total IGF-I, IGFBP-1 and IGFBP-3 levels with incident coronary events and ischemic stroke. J Clin Endocrinol Metab 92: 1319-25, 2007. Times cited (as of 2011): 28

175. Schaffer A, Koushik A, Trottier H, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlee F, Pollak MN, Franco EL; Biomarkers of Cervical Cancer Risk Study Team. Insulin-like growth factor-I and risk of high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 16: 716-22, 2007.

176. Lonn S, Inskip PD, Pollak MN, Weinstein SJ, Virtamo J, Albanes D. Glioma risk in relation to serum levels of insulin-like growth factors. Cancer Epidemiol Biomarkers Prev 16: 844-6, 2007.

177. McSorley MA, Alberg AJ, Allen DS, Allen NE, Brinton LA, Dorgan JF, Pollak M, Tao Y, Helzlsouer KJ. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol 109: 933-41, 2007. Times cited (as of 2011): 25

178. Brisson J, Berube S, Diorio C, Sinotte M, Pollak M, Masse B. Synchronized seasonal variations of mammographic breast density and plasma 25-hydroxyvitamin d. Cancer Epidemiol Biomarkers Prev 16: 929-33, 2007. Times cited (as of 2011): 24

179. *Levitt RJ, Zhao Y, Blouin MJ, Pollak M. The hedgehog pathway inhibitor cyclopamine increase levels of p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells. Cancer Lett 255: 300-6, 2007. Times cited (as of 2011): 16

180. de Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P, Roberts L, Melvin C, Repollet M, Chianese D, Connely M, Terstappen LW, Gualberto A. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 13: 3611-6, 2007. Times cited (as of 2011): 70

181. Pollak MN. Insulin, insulin-like growth factors, insulin resistance, and neoplasia. Am J Clin Nutr 86: S820-1, 2007. Times cited (as of 2011): 18

182. Tworoger SS, Lee IM, Buring JE, Pollak MN, Hankinson SE. Insulin-like growth factors and ovarian risk: a nested case-control study in three cohorts. Cancer Epidemiol Biomarkers Prev 16: 1691-5, 2007.

183. Li H, Bubley GJ, Balk SP, Gaziano JM, Pollak M, Stampfer MJ, Ma J. Hypoxia-inducible factor-1 alpha gene polymorphisms, circulating insulin-like growth factor binding protein-3 levels and prostate cancer. Prostate 67: 1354-61, 2007.

184. Wolpin BM, Michaud DS, Giovannucci EL, Schernhammer ES, Stampfer MJ, Manson JE, Cochrane BB, Rohan TE, Ma J, Pollak MN, Fuchs CS. Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. Cancer Res 67: 7923-8, 2007. Times cited (as of 2011) : 16

185. Michaud DS, Wolpin B, Giovannucci E, Liu S, Cochrane B, Manson JE, Pollak MN, Ma J, Fuchs CS. Prediagnostic plasma C-Peptide and pancreatic cancer risk in men and women. Cancer Epidemiol Biomarkers Prev 16: 2101-9, 2007. Times cited (as of 2011): 28

186. Wolpin BM, Michaud DS, Giovannucci EL, Schernhammer ES, Stampfer MJ, Manson JE, Cochrane BB, Rohan TE, Ma J, Pollak MN, Fuchs CS. Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts. Br J Cancer 97: 98-104, 2007. Times cited (as of 2011): 19

187. Schernhammer ES, Tworoger SS, Eliassen AH, Missmer SA, Holly JM, Pollak MN, Hankinson SE. Body shape throughout life and correlations with IGFs and GH. Endocr Relat Cancer 14: 721-32, 2007. Times cited (as of 2011): 22

188. Rich-Edwars JW, Ganmaa D, Pollak MN, Nakamoto EK, Kleinman K, Tserendolgor U, Willett WC, Frazier AL. Milk consumption and the prepubertal somatotropic axis. Nutr J 6: 28, 2007. Times cited (as of 2011): 20

189. Borugian MJ, Spinelli JJ, Sun Z, Kolonel LN, Oakley-Girvan I, Pollak M, Whittemore AS, Wu AH, Gallagher RP. Prediagnostic C-peptide and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 16: 2164-5, 2007.

190. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67: 10804-12, 2007. Times cited (as of 2011): 151

191. Raina K, Blouin MJ, Singh RP, Majeed N, Deep G, Varghese L, Glode LM, Greenberg NM, Hwang D, Cohen P, Pollak MN, Agarwal R. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 67: 11083-91, 2007. Times cited (as of 2011): 37

192. Singh RP, Deep G, Blouin MJ, Pollak MN, Agarwal R. Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft. Carcinogenesis 28: 2567-74, 2007. Times cited (as of 2011): 24

193. Venkateswaran V, Haddad AQ, Fleshner NE, Fan R, Sugar LM, Nam R, Klotz LH, Pollak M. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst 99: 1793-800, 2007. Times cited (as of 2011): 34

2008

194. Rajpathak SN, McGinn AP, Strickler HD, Rohan TE, Pollak M, Cappola AR, Kuller L, Xue X, Newman AB, Strotmeyer ES, Psaty BM, Kaplan RC. Insulin-like growth factor-axis, inflammation, and glucose intolerance among older adults. Growth Horm IGF Res 18: 166-73, 2008. Times cited (as of 2011): 13

195. Borugian MJ, Spinelli JJ, Sun Z, Kolonel LN, Oakley-Girvan I, Pollak M, Whittemore AS, Wu AH, Gallagher RP. Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: a prospective multiethnic study. Cancer Epidemiol Biomarkers Prev 17: 252-4, 2008.

196. Okereke OI, Pollak MN, Hu FB, Hankinson SE, Selkoe DJ, Grodstein F. Plasma C-peptide levels and rates of cognitive decline in older, community-dwelling women without diabetes. Psychoneuroendocrinology 33: 455-61, 2008.

197. Kaplan RC, McGinn AP, Pollak MN, Kuller L, Strickler HD, Rohan TE, Xue X, Kritchevsky SB, Newman AB, Psaty BM. Total insulin like growth factor 1 and insulin like growth factor binding protein levels, functional status, and mortality in older adults. J Am Geriatr Soc 56: 652-60, 2008.

198. Kasper JS, Liu Y, Pollak MN, Rifai N, Giovannucci E. Hormonal profile of diabetic men and the potential link to prostate cancer. Cancer Causes Control 19: 703-10, 2008. Times cited (as of 2011): 16

199. Ades S, Koushik A, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlée F, Roger M, Franco EL; Biomarkers of Cervical Cancer Risk (BCCR) Study Team (Michael Pollak is member). Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia. Int J Cancer 122: 2820-6, 2008.

200. Diorio C, Brisson J, Berube S, Pollak M. Genetic polymorphisms involved in insulin-like growth factor (IGF-I) pathway in relation to mammographic breast density and IGF levels. Cancer Epidemiol Biomarkers Prev 17: 880-8, 2008. Times cited (as of 2011): 23

201. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, Harris TG, Rohan TE, Xue X, Ho GY, Einstein MH, Kaplan RC, Burk RD, Wylie-Rosett J, Pollak MN, Anderson G, Howard BV, Strickler HD. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarker Prev 17: 921-9, 2008. Times cited (as of 2011): 35

202. van Oijen M, Okereke OI, Kang JH, Pollak MN, Hu FB, Hankinson SE, Grodstein F. Fasting insulin levels and cognitive decline in older women without diabetes. Neuroepidemiology 30: 174-9, 2008.

203. *Algire C, Zakikhani M, Blouin MJ, Shuai JH, Pollak M. Metformin attenuates the stimulatory effect of a high energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer 15: 833-9, 2008. Times cited (as of 2011): 38

204. Diorio C, Brisson J, Berube S, Pollak M. Intact and total insulin-like growth factor-binding protein-3 levels in relation to breast cancer risk factors: a cross-sectional study. Br Cancer Res 10: R42, 2008.

205. Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D, Sharma A, Enriquez Sarano M, Pollak M, Jagannath S, Richardson P, Gualberto A. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulin like growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 26: 3196-203, 2008. Times cited (as of 2011): 59

206. Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN, Bruchim I. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol. 110: 246-50, 2008. Times cited (as of 2011): 29

207. Kaplan RC, McGinn AP, Pollak MN, Kuller L, Strickler HD, Rohan TE, Cappola AR, Xue X, Psaty BM. High insulin like growth factor binding protein 1 level predicts incident congestive heart failure in the elderly. Am Heart J 155: 1006-12, 2008.

208. Max JB, Limburg PJ, Ogunseitan A, Stolzenberg-Solomon RZ, Vierkant RA, Pollak M, Sellers TA, Virtamo J, Cerhan JR, Albanes D. IGF-I, IGFBP-3, and IGF-I/IGFBP-3 Ratio: No Association with Incident Colorectal Cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Cancer Epidemiol Biomarkers Prev 17: 1832-4, 2008.

209. Neuhouser ML, Schenk J, Song YJ, Tangen CM, Goodman PJ, Pollak M, Penson DF, Thompson IM, Kristal AR. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. Prostate 68: 1477-86, 2008.

210. Patel AV, Cheng I, Canzian F, Le Marchand L, Thun MJ, Berg CD, Buring J, Calle EE, Chanock S, Clavel-Chapelon F, Cox DG, Dorronsoro M, Dossu L, Haiman CA, Hankinson SE, Henderson BE, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Linseisen J, Lund E, Manjer J, McCarty C, Peeters PH, Pike MC, Pollak M, Riboli E, Stram DO, Tjonneland A, Travis RC, Trichopoulos D, Tumino R, Yeager M, Ziegler RG, Feigelson HS; Breast and Prostate Cancer Cohort Consortium. IGF-1, IGFBP-1, IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS ONE 3: e2578, 2008. Times cited (as of 2011): 34

211. Page JH, Ma J, Pollak M, Manson JE, Hankinson SE. Plasma insulin-like growth factor 1 and binding-protein 3 and risk of myocardial infarction in women: a prospective study. Clin Chem 54: 1682-8, 2008.

212. Pollak M. Targeting insulin and insulin-like growth factor signalling in oncology. Curr Opin Pharmacol 8: 384-92, 2008. Times cited (as of 2011): 29

213. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen P, Gaziano JM, Pollak M, Stampfer M. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 9: 1039-47, 2008. Times cited (as of 2011): 71

214. *Zakikhani M, Dowling RJO, Sonenberg N, Pollak MN. Effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res 1: 369-75, 2008. Times cited (as of 2011): 46

215. Diorio C, Sinotte M, Brisson J, Berube S, Pollak M. Vitamin d pathway polymorphisms in relation to mammographic breast density. Cancer epidemiol Biomarkers Prev 17: 2505-8, 2008.

216. Fuchs CS, Goldberg RM, Sargen DJ, Meyerhardt JA, Wolpin BM, Green EM, Pitot HC, Pollak M. Plasma insulin-like growth factors, insulin-like binding protein-3 and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res 14: 8263-9, 2008. Times cited (as of 2011): 18

217. Stolzenberg-Solomon RZ, Weinstein S, Pollak M, Tao Y, Taylor PR, Virtamo J, Albanes D. Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. Am J Epidemiol 168: 1047-55, 2008.

218. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV Jr, Helzlsouer K, Rinaldi S, Riboli E, Kaaks R, Janssen JA, Wildhagen MF, Schröder FH, Platz EA, Pollak M, Giovannucci E, Schaefer C, Quesenberry CP Jr, Vogelman JH, Severi G, English DR, Giles GG, Stattin P, Hallmans G, Johansson M, Chan JM, Gann P, Oliver SE, Holly JM, Donovan J, Meyer F, Bairati I, Galan P. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 149: 461-71,W83-8, 2008. Times cited (as of 2011): 68

219. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 14: 6364-70, 2008. Times cited (as of 2011): 73

220. Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res 10: R86, 2008. Times cited (as of 2011): 20

221. Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer 8: 915-28, 2008. Times cited (as of 2011): 290

222. *So AI, Levitt RJ, Eigl B, Fazli L, Muramaki M, Leung S, Cheang MCU, Nielsen TO, Gleave M, Pollak M. Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res 14: 6944-54, 2008. Times cited (as of 2011): 19

223. Pollak M. Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab 22: 625-38, 2008.

224. *Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, Nicholson RI, Carboni J, Gottardis M, Pollak M, Dunn SE. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68: 10238-46, 2008. Times cited (as of 2011): 60

2009

225. Okereke OI, Selkoe DJ, Pollak MN, Stampfer MJ, Hu FB, Hankinson SE, Grodstein F. A profile of impaired insulin degradation in relation to late-life cognitive decline: A preliminary investigation. Int J Geriatr Psychiatry 24: 177-82, 2009.

226. Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, Pollak MN, Giovannucci EL, Fuchs CS. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 27: 176-85, 2009. Times cited (as of 2011): 34

227. Sinotte M, Diorio C, Berube S, Pollak M, Brisson J. Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. Am J Clin Nutr 89: 634-40, 2009. Times cited (as of 2011): 27

228. Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E, Cunningham M, Larsson O, Fazli L, Pollak M. Insulin receptor expression by human prostate cancers. The Prostate 69: 33-40, 2009. Times cited (as of 2011): 44

229. Pollak M. Energy metabolism, cancer risk, and cancer prevention. Recent Results Cancer Res 181: 51-4, 2009.

230. Avnet S, Sciacca L, Salerno M, Gancitano G, Cassarino MF, Longhi A, Zakikhani M, Carboni JM, Gottardis M, Giunti A, Pollak M, Vigneri R, Baldini N. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res 69: 2443-52, 2009. Times cited (as of 2011): 21

231. Pollak M. Aging, IGF-1, and diet. Aging Cell 8: 214, 2009.

232. Kaplan RC, Fitzpatrick AL, Pollak MN, Gardner JP, Jenny NS, McGinn AP, Kuller LH, Strickler HD, Kimura M, Psaty BM, Aviv A. Insulin-like growth factors and leukocyte telomere length: the cardiovascular health study. J Gerontol A Biol Sci Med Sci 64: 1103-6, 2009.

233. Pollak M. Do cancer cells care if their host is hungry? Cell Metab 9: 401-3, 2009.

234. Rohrmann S, Sutcliffe CG, Bienstock JL, Monsegue D, Akereyeni F, Bradwin G, Rifai N, Pollak MN, Agurs-Collins T, Platz EA. Racial variation in sex steroid hormones and the insulin-like growth factor axis in umbilical cord blood male neonates. Cancer Epidemiol Biomarkers Prev 18: 1484-91, 2009.

235. Mavropoulos JC, Buschemeyer WC 3^rd, Tewari AK, Fokhfeld D, Pollak M, Zhao Y, Febbo PG, Cohen P, Hwang D, Devi G, Demark-Wahnefried W, Westman EC, Peterson BL, PIzzo SV, Freedland SJ. The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. Cancer Prev Res (Phila Pa) 2: 557-65, 2009.

236. Dowling RJ, Pollak M, Sonenberg N. Current status and challenges associated with targeting mTOR for cancer therapy. BioDrugs 23: 77-91, 2009. Times cited (as of 2011): 17

237. Su X, Colditz GA, Willett WC, Collins LC, Schnitt SJ, Connolly JL, Pollak MN, Rosner B, Tamimi RM. Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease. Int J Cancer 126: 180-90, 2009.

238. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28: 3009-21, 2009. Times cited (as of 2011): 63

239. Pollak M. Macronutrient intake and cancer: how does dietary restriction influence tumor growth and why should we care? Cancer Prev Res (Phila Pa) 2: 698-701, 2009.

240. Beauchamp MC, Knafo A, Yasmeen A, Carboni JM, Gottardis MM, Pollak MN, Gotlieb WH. BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. Gynecol Oncol 115: 193-8, 2009.

241. Gualberto A, Pollak M. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr Drug Targets 10: 923-36, 2009. Times cited (as of 2011): 20

242. Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin D, Lipton A, Demers L, Leitzel K, Hixon ML, Terstappen LW, Garland L, Paz-Ares LG, Cardenal F, Langer CJ, Gualberto A. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor Figitumumab (CP-751,871) in combination with Paclitaxel and Carboplatin. J Thorac Oncol 4: 1397-403, 2009. Times cited (as of 2011): 19

243. Barbieri M, Paolisso G, Kimura M, Gardner JP, Boccardi V, Papa M, Hjelmborg JV, Christensen K, Brimacombe M, Nawrot TS, Staessen JA, Pollak MN, Aviv A. Higher circulating levels of igf-1 are associated with longer leukocyte telomere length in healthy subjects. Mech Ageing Dev 130: 771-6, 2009.

2010

244. Khalid S, Hwang D, Babichev Y, Kolli R, Altamentova S, Koren S, Goodwin PJ, Ennis M, Pollak M, Sonenberg N, Fantus IG. Evidence for a tumor promoting effect of high-fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis. Breast Cancer Res Treat 122: 647-59, 2010.

245. Tsilidis KK, Brancati FL, Pollak MN, Rifai N, Clipp SL, Hoffman-Bolton J, Helzlsouer KJ, Platz EA. Metabolic syndrome components and colorectal adenoma in the CLUE II cohort. Cancer Causes Control 21: 1-10, 2010.

246. Mucci LA, Stark JR, Pollak MN, Li H, Kurth T, Stampfer MJ, Ma J. Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev 19: 484-91, 2010.

247. *Zakikhani M, Blouin MJ, Piura E, Pollak MN. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 123: 271-9, 2010.

248. Flaig TW, Glode M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su LJ, Li Y, Harrison G, Agarwal R, Crawford ED, Lucia MS, Pollak M. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate 70: 848-55, 2010.

249. Gill JK, Wilkens LR, Pollak MN, Stanczyk FZ, Kolonel LN. Androgens, growth factors, and risk of prostate cancer: the multiethnic cohort. Prostate 70: 906-15, 2010.

250. Neuhouser ML, Till C, Kristal A, Goodman P, Hoque A, Platz EA, Hsing AW, Albanes D, Parnes HL, Pollak M. Finasteride modifies the relation between serum c-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila Pa) 3: 279-89, 2010.

251. *Blouin MJ, Zhao Y, Zakikhani M, Algire C, Piura E, Pollak M. Loss of function of PTEN alters the relationship between glucose concentration and cell proliferation, increases glycolysis, and sensitizes cells to 2-deoxyglucose. Cancer Lett 298: 246-53, 2010.

252. *Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer 17: 351-60, 2010. Times cited (as of 2011): 15

253. Pollak M, Russell-Jones D. Insulin analogues and cancer risk: cause for concern or cause célèbre? Int J Clin Pract 64: 628-36.2010.

254. Okereke OI, Kurth T, Pollak MN, Gaziano JM, Grodstein F. Fasting plasma insulin, c-peptide and cognitive change in older men without diabetes: results from the Physicians’ Health Study II. Neuroepidemiology 34: 200-7, 2010.

255. *Mireuta M, Darnel A, Pollak M. IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription. Growth Factors 28: 243-55, 2010.

256. Schumacher FR, Cheng I, Freedman ML, Mucci L, Allen NE, Pollak MN, Hayes RB, Stram DO, Canzian F, Henderson BE, Hunter DJ, Virtamo J, Manjer J, Gaziano JM, Kolone LN, Tjonneland A, Albanes D, Calle EE, Giovannucci E, Crawford ED, Haiman CA, Kraft P, Willett WC, Thun MJ, Le Marchand L, Kaaks R, Feigelson HS, Bueno-de-Mesquita HB, Palli D, Riboli E, Lund E, Amiano P, Andriole G, Dunning AM, Trichopoulos D, Stampfer MJ, Key TJ, Ma J. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Human Mol Genet 19: 3089-101, 2010.

257. Pollak M. Beyond steroid hormones: the new cancer endocrinology. Lancet Oncol 11: 501-2, 2010.

258. Major JM, Pollak MN, Snyder K, Virtamo J, Albanes D. Insulin-like growth factors and risk of kidney cancer in men. Br J Cancer 103: 132-5, 2010.

259. *Inoue T, Zakikhani M, David S, Algire C, Blouin MJ, Pollak M. Effects of castration on insulin levels and glucose tolerance in the mouse differ from those in man. Prostate 70: 1628-35, 2010.

260. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. CA Cancer J Clin 60: 207-21, 2010. Times cited (as of 2011): 31

261. Hou M, Venier N, Sugar L, Musquera M, Pollak M, Kiss A, Fleshner N, Klotz L, Venkateswaran V. Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet. BiochemBiophys Res Commun 397: 537-42, 2010.

262. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. Diabetes Care 33: 1674-85, 2010.

263. Canzian F, Cox DG, Setiawan VW, Stram DO, Ziegler RG, Dossus L, Beckmann L, Blanche H, Barricarte A, Berg CD, Bingham S, Buring J, Buys SS, Calle EE, Chanock SJ, Clavel-Chapelon F, Delancey JO, Diver WR, Dorronsoro M, Haiman CA, Hallmans G, Hankinson SE, Hunter DJ, Husing A, Isaacs C, Khaw KT, Kolonel LN, Kraft P, Le Marchand L, Lund E, Overvad K, Panico S, Peeters PH, Pollak M, Thun MJ, Tjonneland A, Trichopoulous D, Tumino R, Yeager M, Hoover RN, Riboli E, Thomas G, Henderson BE, Kaaks R, Feigelson HS. Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI Breast and Prostate Cancer Cohort Consortium. Hum Mol Genet 19: 3873-84, 2010.

264. Douglas JB, Silverman DT, Pollak MN, Tao Y, Soliman AS, Stolzenberg-Solomon RZ. Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 19: 2298-306, 2010.

265. Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, Petroulakis E, Robichaud N, Pollak M, Gaboury LA, Pandolfi PP, Saad F, Sonenberg N. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci USA 107: 14134-9, 2010.

266. Johnson JA, Pollak M. Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes. Diabetologia 53: 2086-8, 2010.

267. Major JM, Stolzenberg-Solomon RZ, Pollak MN, Snyder K, Virtamo J, Albanes D. Insulin-like growth factors and liver cancer risk in male smokers. Br J Cancer 103: 1089-92, 2010.

268. Thomas JA 2^nd, Antonelli JA, Lloyd JC, Masko EM, Poulton SH, Phillips TE, Pollak M, Freedland SJ. Effect of intermittent fasting on prostate cancer tumor growth in a mouse model. Prostate Cancer Prostatic Dis 13: 350-5, 2010.

269. Grimaldi-Bensouda L, Marty M, Pollak M, Cameron D, Riddle M, Charbonnel B, Barnett AH, Boffetta P, Boivin JF, Evans M, Rossignol M, Benichou J, Abenhaim L; ISICA group. The international study of insulin and cancer. Lancet 376: 769-70, 2010.

270. Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila) 3: 1060-5, 2010. Times cited (as of 2011): 20

271. Potratz JC, Saunders DN, Wai DH, Ng TL, McKinney SE, Carboni JM, Gottardis MM, Triche TJ, Jurgens H, Pollak MN, Aparicio SA, Sorensen PH. Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas. Cancer Res 70: 8770-81, 2010.

2011

272. Bordeleau L, Lipscombe L, Lubinski J, Ghadirian P, Foulkes WD, Neuhausen S, Ainsworth P, Pollak M, Sun P, Narod SA; the Hereditary Breast Cancer Clinical Study Group. Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. Cancer 117: 1812-18, 2011.

273. *Algire C, Amrein L, Bazile M, David S, Zakikhani M, Pollak M. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene 30: 1174-82, 2011.

274. Takahara K, Tearle H, Ghaffari M, Gleave ME, Pollak M, Cox ME. Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgen-independent progression. Prostate 71: 525-37, 2011.

275. Tognon CE, Somasiri AM, Evdokimova VE, Trigo G, Uy EE, Melnyk N, Carboni JM, Gottardis MM, Roskelley CD, Pollak M, Sorensen PH. ETV6-NTRK3 mediated breast epithelial cell transformation is blocked by targeting the IGF1R signalling pathway. Cancer Res 71: 1060-70, 2011.

276. Azoulay L, Dell’aniello S, Gagnon, Pollak MN, Suissa S. Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev 20: 337-44, 2011.

277. Douglas JB, Silverman DT, Weinstein SJ, Graubard BI, Pollak MN, Tao Y, Jarmo V, Albanes D, Stolzenberg-Solomon R. Serum C-reactive protein and risk of pancreatic cancer in two nested, case-control studies. Cancer Epidemiol Biomarkers Prev 20: 359-69, 2011.

278. Gualberto A, Hixon ML, Karp DD, Li D, Green S, Dolled-Filhart M, Paz-Ares LG, Novello S, Blakely J, Langer CJ, Pollak MN. Pre-treatment levels of circulating free IGF-I identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer 104: 68-74, 2011.

279. Kaplan RC, Petersen AK, Chen MH, Teumer A, Glazer N, Doring A, Lam CS, Friedrich N, Newman A, Muller M, Yang Q, Homuth G, Cappola A, Klopp N, Smith H, Ernst F, Psaty BM, Wichmann HE, Sawyer DB, Biffar R, Rotter JI, Gieger C, Sullivan LS, Volzke H, Rice K, Spyroglou A, Kroemer HK, Chen YD, Manalopoulou J, Nauck M, Strickler HD, Goodarzi MO, Reincke M, Pollak MN, Bidlingmaier M, Vasan RS, Wallaschofski H. A genome-wide association study identifies novel loci associated with circulating IGF-I and IGFBP-3. Hum Mol Genet 20: 1241-51, 2011.

280. Nimptsch K, Platz EA, Pollak MN, Kenfield SA, Stampfer MJ, Willett WC, Giovannucci E. Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993-2004. Int J Cancer 128: 660-7, 2011.

281. Ng K, Sargent DJ, Goldberg RM, Meyerhardt JA, Green EM, Pitot HC, Hollis BW, Pollak MN, Fuchs CS. Vitamin D status in patients with stage IV colorectal cancer: Finding from intergroup trial N9741. J Clin Oncol 29: 1599-606, 2011.

282. *Mireuta M, Hancock MA, Pollak M. Binding between insulin-like growth factor 1 and insulin-like growth factor binding protein 3 is not influenced by glucose or 2-deoxy-D-glucose. J Biol Chem 286: 16567-73, 2011.

283. Yasmeen A, Beauchamp MC, Piura E, Segal E, Pollak M, Gotlieb WH. Induction of apoptosis by metformin in epithelial ovarian cancer: Involvment of the Bcl-2 family proteins. Gynecol Oncol 121: 492-8, 2011.

284. Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, Pollak M, Turashvili G, Gilks BC, Kennecke H. Insulin-like growth factor receptor in breast cancer subtypes. Breast Cancer Res Treat. 2011 May 15. Epub ahead of print.

285. Suissa A, Azoulay L, Dell’aniello S, Evans M, Vora J, Pollak M. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia 54: 2254-62, 2011.

286. Lipton A, Chapman JA, Demers L, Shepherd LE, Han L, Wilson CF, Pritchard KI, Leitzel KE, Ali SM, Pollak M. Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA. 14. J Clin Oncol 29: 3605-10, 2011.

287. Poole EM, Tworoger SS, Hankinson SE, Schernhammer ES, Pollak MN, Baer HJ. Body size in early life and adult levels of insulin-like growth factor 1 and insulin-like growth factor binding protein 3. Am J Epidemiol 174: 642-51, 2011.

288. *Mashhedi H, Blouin MJ, Zakikhani M, David S, Zhao Y, Bazile M, Birman E, Algire C, Aliaga A, Bedell BJ, Pollak M. Metformin abolishes increased tumor (18)F-2-Fluoro-2-Deoxy-D-Glucose uptake associated with a high-energy diet. Cell Cycle 10: 2770-8, 2011.

289. Medyouf H, Gusscott S, Wang H, Tseng JC, Wai C, Nemirovsky O, Trumpp A, Pflumio F, Carboni J, Gottardis M, Pollak M, Kung AL, Aster JC, Holzenberger M, Weng AP. High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signalling. J Exp Med 208: 1809-22, 2011.

290. Tognon CE, Martin MJ, Moradian A, Trigo G, Rotblat B, Cheng SW, Pollard M, Uy E, Chow C, Carboni JM, Gottardis MM, Pollak M, Morin GB, Sorensen PH. A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation. Oncogene. 2011 Aug 1. Epub ahead of print.

291. Lubik AA, Gunter JH, Hendy SC, Locke JA, Adomat HH, Thompson V, Herington A, Gleave ME, Pollak M, Nelson CC. Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Res 71: 5754-64, 2011.

292. Gao Y, Katki H, Graubard B, Pollak M, Martin M, Tao Y, Schoen RE, Church T, Hayes RB, Greene MH, Berndt SI. Serum IGF1, IGF2, and IGFBP3 and risk of advanced colorectal adenoma. Int J Cancer. 2011 Sep 19. Epub ahead of print.

293. Pritchard KI, Shepherd LE, Chapman JA, Norris BD, Cantin J, Goss PE, Dent SF, Walde D, Vandenberg TA, Findlay B, O’Reilly SE, Wilson CF, Han L, Piura E, Whelan TJ, Pollak MN. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA 14. J Clin Oncol 29: 3869-76, 2011.

294. Zhang X, Giovannucci EL, Smith-Warner SA, Wu K, Fuchs CS, Pollak M, Willett WC, Ma J. A prospective study of intakes of zinc and heme iron and colorectal cancer risk in men and women. Cancer Causes Control 22: 1627-37, 2011.

295. Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P, Wood L, Pollak M, Berry S, Lattouf JB, Mukherjee SD, Gleave M, WInquist E; for the Canadian Uro-Oncology Group. Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res 17: 5765-73, 2011.

296. Gualberto A, Hixon ML, Pollak M. Reply: ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’. Br J Cancer 105: 1467, 2011.

297. Segal Ed, Yasmeen A, Beauchamp MC, Rosenblatt J, Pollak M, Gotlieb WH. Relevance of the OCT1 transporter to the antineoplastic effect of biguanides. Biochem Biophys Res Commun 414: 694-9, 2011.

298. Faupel-Badger JM, Wang Y, Karumanchi SA, Stanczyk F, Pollak M, McElrath T, Hoover RN, Troisi R. Associations of pregnancy characteristics with maternal and cord steroid hormones, angiogenic factors, and insulin-like growth factor axis. Cancer Causes Control 22: 1587-95, 2011.

299. *Dool C, Mashhedi H, Zakikhani M, David S, Zhao Y, Birman E, Carboni JM, Gottardis M, Blouin MJ, Pollak MN. IGF-1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin responsive breast cancer. Endocr Relat Cancer 18: 699-709, 2011.

300. Dhillon PK, Penney KL, Schumacher F, Rider JR, Sesso HD, Pollak M, Fiorentino M, Finn S, Loda M, Rifai N, Mucci LA, Giovannucci E, Stampfer MJ, Ma J. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 20: 2618-27, 2011.

301. Wu K, Feskanich D, Fuchs CS, Chan AT, Willett WC, Hollis BW, Pollak MN, Giovannucci. Interactions between plasma levels of 25-hydroxyvitamin D, insulin-like growth factor (IGF)-1 and c-peptide with risk of colorectal cancer. PLoS One 6: e28520, 2011.

2012

302. Pollak M. The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clini Cancer Res 18: 40-50, 2012.

303. *Algire C, Moiseeva O, Deschenes-Simard X, Amrein L, Petruccelli LA, Birman E, Viollet B, Ferbeyre G, Pollak MN. Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev Res (Phila). 2012 Jan 18. Epub ahead of print.

304. Agurs-Collins T, Rohrmann S, Sutcliffe C, Bienstock JL, Monsegue D, Akereyeni F, Bradwin G, Rifai N, Pollak MN, Platz EA. Racial variation in umbilical cord blood sex steroid hormones and the insulin-like growth factor axis in African-American and white female neonates. Cancer Causes Control. 2012 Jan 18. Epub ahead of print.

Book Chapters, Letters, Serials

1. Pollak M. Epidermal growth factor receptors and breast cancer. (letter) Lancet. 2: 562, 1987.

2. Pollak M. Recombinant GM-CSF in myelosuppression of chemotherapy. (letter) New England Journal of Medicine. 320: 253-4, 1989.

3. Pollak M. Review Bias. (letter) New England Journal of Medicine. 322: 638, 1989.

4. Pollak M. Therapeutic Implications of Recent Growth Factor Research. in High Risk Breast Cancer, Ragaz J (ed), Springer Verlag, New York, 1991.

5. Pollak M. Timing of surgery in breast cancer. (letter) Lancet. 337: 1603-4, 1991.

6. Pollak M. Reference for patients: valuable or misguided? (book review of: Everyone’s Guide to Cancer Therapy Dollinger M.) J Can Med Assoc. 147: 213-4, 1992.

7. Pollak M. Effects of adjuvant tamoxifen therapy on growth hormone and IGF-1 physiology. in Salmon S. (ed.) Adjuvant Therapy of Cancer VII Lipincott, Philadelphia, 43-55, 1993.

8. Arbour L, Narod S, Glendon G, Pollak M., Seymour R, Miner L, Leung P. In vitro fertilization and family history of breast cancer. (letter) Lancet. 344: 610-1, 1994.

9. Pollak M. Potential impact of genetic testing on cancer prevention trials, using breast cancer as an example. (letter) J Natl Cancer Inst. 87: 1557-8, 1995.

10. Pollak M. Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. (letter) J Natl Cancer Inst. 87: 458, 1995.

11. Pollak M. Reversal by transferrin of growth-inhibitory effect of suramin on hormone-refractory human prostate cancer cells. (letter) J Natl Cancer Inst. 87: 608-9, 1995.

12. Pollak M. Enhancement of the antineoplastic effects of tamoxifen by somatostatin analogues. in Kellen J. (ed.) Tamoxifen: Beyond the Antiestrogen Birkhauser, Boston, 359-68, 1996.

13. Pollak M. Hormonal therapies for breast cancer. Current Oncology. 3: s46-s52, 1996.

14. Pollak M. The potential role of somatostatin analogues in the management of breast cancer. Peptide Therapy Reviews. 8: 1-13, 1996.

15. Pollak M, Ingle J, Suman V, Kugler J. Rationale for combined antiestrogen-somatostatin analogue therapy of breast cancer. in Salmon S. (ed.) Adjuvant Therapy of Cancer VIII Lipincott, Philadelphia, 145-52, 1997.

16. Pollak M. Cancer controversy. Nature. 392: 752, 1998.

17. Ma J, Giovannucci E, Pollak M, Stampfer M. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein 3. (letter) J Natl Cancer Inst. 91: 2051-2, 1999.

18. Pollak M. American Society for Clinical Oncology: Online continuing medical education segment. Published on Web. www.conference-cast.com/ASCO, 1999.

19. Pollak, M. IGF-I, IGFBP-3 and Cancer Risk: An Update. (letter) Topical Endocrinology Suppl. 7: 18-9, 2000.

20. Pollak M, Besser M, Cohen P, Rosenfeld R. Overview: First International Workshop on Growth Hormone, Insulin-like Growth Factors and Neoplasia. Growth Horm IGF Res. 10 Suppl A: 1-3, 2000.

21. Pollak M. Insulin-like growth factor physiology and neoplasia. Growth Horm IGF Res. 10 Suppl A: 6-7, 2000.

22. Byrne C, Hankinson S, Pollak M, Willett W, Colditz G, Speizer F. Insulin-like growth factors and mammographic density. Growth Horm IGF Res. 10 Suppl A: 24-5, 2000.

23. Ma J, Pollak M, Giovannucci E, Chan J, Tao Y, Hennekens C, Stampfer M. A prospective study of plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3, and colorectal cancer risk among men. Growth Horm IGF Res. 10 Suppl A: 28-9, 2000.

24. Giovannucci E, Pollak M, Platz E, Willett W, Stampfer M, Majeed N, Colditz G, Speizer F, Hankinson S. Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and the risk of colorectal adenoma and cancer in the Nurses' Health Study. Growth Horm IGF Res. 10 Suppl A: 30-1, 2000.

25. Chan J, Stampfer M, Giovannucci E, Ma J, Pollak M. Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and prostate cancer risk: epidemiological studies. Growth Horm IGF Res. 10 Suppl A: 32-3, 2000.

26. Ma J, Stampfer M, Pollak M. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF- binding protein-3. (letter) J Natl Cancer Inst. 92: 1949, 2000.

27. Pollak M. Serum IGF-I, IGF-II, and IGFBP-3 Levels and Cancer Risk. Published on Web. www.dslabs.com/dslabs/1998_sabm.htm, 2000.

28. Pollak M. How do anti-oestrogens work? in Tobias J, Houghton J, and Henderson I. (eds.) Breast Cancer: New Horizons in Research and Treatment Oxford University Press, New York, 2001.

29. Pollak M. IGF-I, Insulin and Cancer Risk: Linking the Biology and the Epidemiology. In LeRoith D, Zumkeller W, Baxter R. (eds.) Insulin-Like Growth Factors (chapter 20) Eurekah.com. , 2003.

30. Narasimhadevara R, Pollak MN, Foulkes WD. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. (letter) J Natl Cancer Inst. 95: 917-9, 2003.

31. Pollak M. Insulin-like growth factors and neoplasia. Novartis Found Symp. 262: 84-8, 98-107, 265-8, 2004.

32. Pollak M. Individualizing Interventions for Cancer Prevention. in Senn H-J, Morant R.(eds.) Recent Results in Cancer Research 166: 63-70, 2005.

INVITED LECTURES

(Only a subset of presentations is listed.)

1984

Memorial University, Newfoundland, November

Grand Medical Rounds

1985

Jewish General Hospital, Montreal, annually to present

Grand Medical Rounds

1986

Montreal General Hospital, Montreal, November

Oncology Rounds

Lady Davis Institute, Montreal, December

Molecular Biology Seminar

1987

Royal Victoria Hospital, Montreal, February

Interdisciplinary Oncology Rounds

McGill Cancer Center, Montreal, February

Research Seminar

Department of Medicine, Jewish General Hospital, Montreal, February

Staff Research Seminar

Notre-Dame Hospital, Montreal, February

Interhospital Oncology Rounds

Bristol Myers Company, Wallingford, CT, November

Novel hormonal cancer therapies

Lady Davis Institute for Medical Research, Montreal, December

Staff Seminar

1988

Jewish General Hospital, Montreal, January

Surgical Grand Rounds

NSABP-NCI Annual Meeting, Tampa, January

Plenary Session, Incorporating basic science investigations into clinical trials

Sandoz Canada, Dorval, Quebec, June

Invited Speaker

Montreal General Hospital, Montreal, June

Grand Medical Rounds

Somatostatin analogues in cancer therapy workshop, Sandoz Pharma, Basle, Switzerland, October

Invited Participant

1989

First Annual European Winter Oncology Conference, Crans-Montana, Switzerland, January

Mechanisms of action of somatostatin analogues as antineoplastic agents

National Cancer Institute of Canada Clinical Trials Group Meeting, Montreal, April

Breast Cancer Session, Innovative Hormonal Treatments for Breast Cancer

Mamonides Hospital, Montreal, October

Grand Rounds, Breast Cancer

1990

Montreal General Hospital, Montreal, January

Oncology Rounds

Jewish General Hospital, Montreal, April

Family Practice Rounds, The role of the primary care physician in oncology care

NCIC Clinical Trials Group Meeting, Toronto, April

IGF-I and sarcomas

NCIC Pharmacists’ Meeting, Toronto, April

Prostate cancer: treatment strategies

Reunion Interhospitaliere en Oncologie Medicale, Montreal, May

Invited Speaker

Lake Ontario Metastasis Group Meeting, Hamilton, Ontario, June

Invited Speaker

Princess Margaret Hospital and Bayview Regional Cancer Center, Toronto, October

Invited Speaker

NCIC Terry Fox sarcoma conference, London, Ontario, December

Invited Participant

1991

2nd international symposium on IGF-I, San Francisco, January

Plenary Session

Royal Marsden Hospital, London, UK, February

Invited Speaker

Jewish General Hospital, Montreal, March

Grand Medical Rounds

McGill University, Department of Clinical Biochemistry, Montreal, March

Research Seminar

Princess Margaret Hospital, Toronto, April

Grand Rounds, IGF-I role in sarcomas

Somatostatin–State of the Art Symposium, Monte Carlo, October

Plenary Session

McGill Cancer Center, Montreal, November

Somatomedins in cancer

Department of Endocrinology, Montreal Children’s Hospital, Montreal, November

In vitro studies concerning responsivity of human cancers to somatomedins

University of Ottawa, Ottawa, November

IGF-I in breast cancer

1992

Hope and Cope Members Meeting, Montreal, January

Non-cytotoxic cancer treatments

Queens University, Kingston, Ontario, February

Somatomedins and cancer - opportunities for basic science components within clinical trials

NCIC Breast Cancer Meeting, Niagara Falls, March

IGF-I in breast cancer

University of Toronto Breast Cancer Conference, Toronto, April

Effect of tamoxifen on IGF-I physiology

NCIC Clinical Trials Conference, Toronto, April

Somatostatin analogues as novel agents in breast cancer

IGF Workshop, Nice, France, August

Invited Speaker

NCI-NIH, Bethesda, MD, USA, September

IGF and Sarcomas

Reichmann Research Institute, Sunnybrook Hospital, Toronto, October

Invited Speaker

Jewish General Hospital, Montreal, December

New Developments in Hormonal Treatment of Cancer

NSABP Biological Markers Committee Meeting, Hilton Head, December

IGF-1 as potential intermediate end point in prevention studies

CALGB Breast Committee Meeting, Washington, DC, December

Somatostatin analogues as potential agents for breast cancer

1993

NCIC symposium on cancer research, Laval University, Quebec City, January

Invited Speaker

Tucson Adjuvant Therapy Conference, Tucson, March

Plenary Session, Invited Speaker

Institute Henry Beaufort, Washington, DC, March

Invited Speaker

Vanderbilt University, Nashville, April

Grand Rounds and Faculty Club lectures Visiting Professor

NSABP protocol design committee meeting, Pittsburgh, June

Somatostatin-antiestrogen interactions: preclinical and early clinical data

Sandoz Research Institute, East Hanover, NJ, July

Somatostatin-antiestrogen synergy

NSABP Group Meeting, Chicago, October

Tamoxifen-somatostatin interactions

Mount Sinai Hospital Chemotherapy Foundation, New York City, November

Newly described mechanisms of action of tamoxifen

Sandoz Research Institute, East Hanover, NJ, November

Novel oncological applications of hypothalamic releasing factor analogues

American Health Foundation, New York City, December

Tamoxifen effects on IGF-I physiology: relationships to efficacy and toxicity of the drug

1994

International IGF meeting, Sydney, Australia, January

Plenary Lecture, IGFBP-4 linkage to hereditary breast cancer

(presentation delegated to a colleague)

Sandoz Research Center, Basle, Switzerland, March

Somatostatin analogues and neoplasia

Lancet Breast Cancer Conference, Brussels, Belgium, April

Plenary session, IGF system of mitogens and breast cancer

Tamoxifen-Sandostatin multinational trial meetings, London, England and Montreal, June

Rationale for combining antiestrogens and somatostatin analogues in breast cancer treatment

Karolinska Institute, Stockholm, Sweden, June

Academic Visitor

(1) A novel tumor suppressor gene on chromosome 1p35

(2) IGF binding proteins in breast cancer

NSABP group meeting, Tampa, June

Plenary session speaker, Rationale for clinical trials involving somatostatin analogues combined with antiestrogens in the treatment of breast cancer

1995

Hadassah Hospital, Hebrew University, Jerusalem, Israel, January

Visiting Professor and lecturer, IGF system of mitogens and neoplasia

Somatostatin Symposium, Eilat, Israel, January

Oncological applications of somatostatin analogues

NSABP protocol design committee meeting, Washington, DC, January

Rationale for clinical trials involving somatostatin analogues combined with antiestrogens in the treatment of breast cancer

5th Breast Cancer Adjuvant Therapy Symposium, St. Gallen, Switzerland, March

Growth factors and neoplasia: recent progress

Hamilton Regional Cancer Center, Hamilton, Ontario, April

Oncology Grand Rounds, Pathophysiology of somatomedins in neoplasia

National Cancer Institute of Canada Clinical Trials Group Meeting, Toronto, May

Proposed tamoxifen-octreotide adjuvant trial design

Human Genome Sciences, Inc., Washington, DC, August

Relating gene discovery to physiology: the case of MDGI

Octreotide Clinical Research Meeting, Sandoz Research Institute, Frankfurt, September

Breast cancer and octreotide

Nottingham Breast Cancer Meeting, Nottingham, UK, September

Discussion group participant, IGF-related serum markers in breast cancer

International symposium on IGF binding proteins, Tubingen, Germany, October

Invited Plenary Speaker, IGFBPs and antiestrogen action

Harvard School of Public Health, Boston, October

IGF-I, nutrition, body size, and neoplasms of colon and breast: new relationships

Chemotherapy Foundation Symposium XIII, New York City, November

Somatostatin analogues: mechanisms of action as antineoplastics

European Federation of Endocrine Societies Meeting, Sorrento, Italy, November

Somatostatin analogs: basic and clinical perspectives

Montreal General Hospital Research Institute Seminar Series, Montreal, December

IGFs in breast cancer pathogenesis

1996

Royal Victoria Hospital, Montreal, January

Medical Grand Rounds, New directions in cancer endocrinology

Orion Pharmos, Turku, Finland, January

Antiestrogen action: involvement of insulin-like growth factors

Site review of NSABP by NCI (USA), Pittsburgh, February

Invited Speaker

NSABP general meeting, Orlando, March

Invited Speaker

8th International Conference on the adjuvant therapy, Scottsdale, Arizona, March

Plenary session, Enhancement of tamoxifen-induced suppression of serum IGF-1 levels in metastatic breast cancer patients by co-administration of the somatostatin analogue octreotide

McGill Continuing Medical Education Program, Montreal, March

47th Refresher Course for Family Physicians

Controversies surrounding breast cancer genetic testing

NCIC Clinical Trials Group Meeting, Toronto, April

The MA14 Trial

International Association of Pancreatology, Mannheim, Germany, June

Invited Speaker (presentation delegated to a colleague)

Scherring-Plough Antiestrogen Symposium, Bermuda, July

Invited Speaker

National Cancer Institute/NIH (USA), Bethesda, MD, October

IGFs: biological and epidemiological evidence for a relationship to breast cancer

Yale University, New Haven, CT, November

Plenary speaker, Biology and clinical relevance of somatostatin receptor

University of British Columbia, Vancouver, December

Visiting Professor

(1) IGF binding proteins in post-lactational involution and antiestrogen action.

(2) Novel non-cytotoxic approaches to sarcoma treatment

(3) Mammary derived growth inhibitor: role in breast differentiation and pathophysiology in breast cancer

(4) Somatostatin-antiestrogen interactions: the MA14 trial

1997

University of Pittsburgh, Pittsburgh, March

Prospects for non-cytotoxic therapy of pancreatic cancer

Biochem Pharma, Montreal, April

Novel natural source metalloproteinase inhibitors.

McGill Endocrinology Department Retreat, Montreal, May

Invited Speaker

Ron Buick Memorial Symposium, University of Toronto, Toronto, May

Translational research: case studies in Oncology

European Endocrine Society Meeting, Sorrento, Italy, June

Mechanism of action of noncytotoxic anticancer therapies: octreotide

McGill Oncology Department Beer “Chalk Talk”, Montreal, September

IGFs and neoplasia—new data

Scripps Clinic, University of California, San Diego, October

Invited Speaker

World Insulin-like growth factor Congress, Tokyo, October

Invited Speaker

“Tamoxifen and the Uterus” symposium, Brussels, December

Invited Speaker

1998

Bayview Regional Cancer Center, Toronto, January

A novel risk factor for breast and prostate cancer

6th International Conference on Adjuvant therapy, St Gallen, Switzerland, February

Invited Speaker

Annual Meeting of the American Association for Cancer Research, “Molecular basis of cancer susceptibility” symposium, New Orleans, March

Invited Speaker

Novartis Pharma, meeting of experts on prostate cancer, New Orleans, March

Invited Speaker

Merck Pharma, Rahway, New Jersey, April

Invited Speaker

Cancer Center of New Jersey, New Brunswick, New Jersey, April

Invited Speaker

Novartis Pharmaceuticals, Basle, Switzerland, April

External Experts consultative session regarding somatostatin analogues

Cancer Prevention Lecture Series, University of Toronto, Toronto, April

Invited Speaker

National Cancer Institute of Canada Annual Meeting, Montreal, May

Invited Speaker

Axys Pharma, San Francisco, May

Invited Speaker

Annual Meeting of the American Society of Clinical Oncology, Los Angeles, May

“Issues in early breast cancer” symposium

Invited Speaker

Cancer Control Agency of British Columbia, Vancouver, June

Invited Speaker

Montreal Children’s Hospital, Montreal, June

IGFs and cancer risk

The Jackson Laboratory, Bar Harbor, Maine, August

Invited Speaker

Cadus Pharmaceuticals, New York, September

Invited Speaker

CAPCURE Annual Meeting, Lake Tahoe, September

Invited Participant

DSL IGF World Experts Symposium, Oregon, September

Invited Speaker

McGill University, Department of Anatomy, Montreal, September

Rates of epithelial cell turnover and IGF-1

Royal College of Physicians and Surgeons Annual Meeting, Toronto, September

Invited Speaker (unable to attend)

University of Toronto Prostate Cancer Symposium, Toronto, October

Invited Speaker

Residents lecture series–McGill University, Montreal, October

Prostate Cancer

Danna Farber Cancer Center, Harvard University, Boston, October

Invited Speaker

Axys Pharmaceuticals, San Diego, December

Invited Speaker

KIGS National Meeting, Laguna Niguel, California, December

Plenary Session speaker, The GH-IGF axis and neoplasia

1999

Zeneca Pharma, Montreal, March

New aspects of gonadal steroid ablation therapy

Sunnybrook-Women’s College Hospital, Toronto, March

Oncology Grand Rounds, Gonadal steroid ablation therapy

Chemoprevention Branch, National Cancer Institute USA, Bethseda, MD, March

Invited Speaker

Ipsen Biotech, Boston, March

Drug development opportunities related to advances in growth factor research

Pediatric brain tumor endocrinology group, San Francisco, April

Invited Speaker

British Endocrine Societies, Annual Meeting, Bournemouth, UK, April

Plenary session, Invited Speaker

NCIC Clinical Trials Group, Toronto, April

MA14 Clinical Trial: Progress

Senate Committee Hearing, Government of Canada, Ottawa, April

Expert witness regarding bovine somatropin

Department of Endocrinology, Jewish General Hospital, Montreal, May

Cancer Endocrinology

Biochem Pharma, Montreal, May

Novel molecular targets for antineoplastic therapy

Late breaking research AACR session, Philadelphia, April

Selected presentation, Relationship of colorectal cancer risk to serum IGF-I and IGFBP-3 levels

ASCO Annual Meeting, Atlanta, May

IGF-I physiology and colorectal cancer risk

Harvard University Center for Cancer Prevention, Boston, June

Workshop on IGF and cancer risk, Invited Speaker

Lilly Global Medical Conference, Indianapolis, June

Prospects for pharmacological reduction of cancer risk

National Meeting of Canadian Breast Cancer Research Initiative, Toronto, June

IGF physiology: clues for new approaches to breast cancer research and treatment

Canadian Urological Society Meeting, London, Ontario, June

IGF physiology: relevance to prostate cancer biology

Institut Ipsen-Beaufort, Paris, France, July

Somatostatin and neoplasia

Chemoprevention Branch Prostate Cancer Prevention Symposium, National Cancer Institute, Washington, DC, August

Invited Speaker (presentation delegated to a colleague)

NSABP clinical trials group, Toronto, August

B29 trial: update regarding rationale and experience to date

Pharmacia Upjohn Growth Hormone Congress, Boston, October

IGF physiology and cancer risk

International Workshop on growth hormone, Insulin-like growth factors and neoplasia, Boston, October

Invited Speaker

International Symposium on IGFs, Brighton, UK, October

Invited Speaker

UICC Cancer Prevention Symposium, Beijing, China, October

Invited Speaker (presentation delegated to a colleague)

AACR Meeting on “Biology of cancer risk”, Bal Harbor, Florida, October

IGF biology and cancer prevention

CAPCURE 6th annual Scientific Retreat, Lake Tahoe, Nevada, October

Invited Delegate

Princess Margaret Hospital, Toronto, December

IGF physiology and breast cancer: basic and translational aspects

2000

UICC Prostate Cancer Symposium, Eilat, Israel, January

Peptide growth factors: Relevance to prostate cancer

Tumor Prevention and Genetics 2000 Symposium, St Gallen, Switzerland, February

Invited Speaker

M.D. Anderson Hospital, Houston, Texas, March

Invited Speaker

National Cancer Institute of Canada Clinical Trials Meeting, Toronto, April

Invited Speaker

Bristol Myers-Squibb, Pharma, New Jersey, April

Invited Speaker

19th International Meeting on Endocrinology and Development, Sorrento, Italy, May

Invited Speaker

3rd International Workshop of the Growth Hormone Research Society, Washington, D.C., May

Invited Delegate

“Hormonal Carcinogenesis” International Conference, St. Petersburg, Russia, May

Invited Speaker

Endocrine Society Annual Meeting, Plenary Session, Toronto, June

Invited Speaker

International Symposium on IGFs and Cancer, Halle, Germany, September

Invited Speaker

CAPCURE 7th annual Scientific Retreat, Lake Tahoe, Nevada, September

Invited Delegate

International Endocrine Congress, Plenary Session, Sydney, Australia, October

Invited Speaker

NCI (USA) Symposium on physical activity and cancer risk, Dallas, Texas, November

Invited Speaker

2001

Millennium Pharmaceuticals, Boston, February

Invited Speaker

Mc Gill University, Centre for Clinical Epidemiology and Community Studies, Montreal, February

IGF and Cancer risk

Federation of General Surgeons of Quebec, May

Invited Speaker

Axys Pharmaceuticals, South San Francisco, June

Invited Speaker

Astra-Zeneca IMPACT meeting, Manoir Richelieu, Quebec, June

Invited Speaker

Fred Hutchinson Comprehensive Cancer Center, Seattle, June

IGFs: Potential Relevance to cancer prevention & treatment

8^th Annual Meeting of CAPCURE. Lake Tahoe, September

Invited Speaker

“A mechanism of androgen-independence related to IGF signaling in prostate cancer.”

McGill University Health Science Center, Montreal, December

Invited Speaker, Urology Department, “Insulin-like growth factors and prostate cancer.”

2002

University Health Network-Princess Margaret Hospital, Toronto, January

Oncology Grand Rounds, “Insulin-like growth factors: relevance to prostate cancer.”

Diagnostic Systems Limited, Houston, Texas, January

Invited Speaker, “Methods in IGF measurements.”

Telik Inc., San Francisco, California, January

Invited Speaker, “IGF signaling in neoplasia: opportunities for drug development.”

NCIC Clinical trial group, Toronto, February

“Future of Breast Cancer Treatment” Workshop, “Herceptin resistance and IGF signaling.”

Albert Einstein University, New York City, February

Invited Speaker, “Endocrine epidemiology of IGF’s.”

Prostate Cancer Prevention Trial Management Committee, South West Oncology Group,

Invited Speaker

San Antonio, Texas, February

“Prostate Cancer Prevention: New Opportunities.”

EORTC European Breast Cancer Congress, Barcelona, Spain, March

Invited Speaker, “Biology underlying breast cancer prevention strategies”

EORTC European Breast Cancer Congress, Barcelona, Spain, March

Oral Presentation, “MA14 Adjuvant Breast Cancer Treatment Trial”

Gordon Conference on “New frontiers in cancer detection and diagnosis”, Ventura Beach, California, March

Invited Speaker, “Host factors influencing rate of carcinogenesis: the case of insulin-like growth factors”

AACR Annual meeting, San Francisco, April

Invited Speaker, “Daybreak-Meet-the-Expert-Session” IGF’s and Neoplasia

Novartis Opinion Leaders Meeting, Switzerland, June

Invited Participant

Astra-Zeneca Opinion Leaders Meeting, New York City, July

Invited Participant

16^th World Congress of Epidemiology, Montreal, August

Invited Speaker

CaPCURE Annual Meeting, Washington D.C., September

Invited Participant

Canadian Endocrinology Society Annual Meeting, Vancouver, October

“New Frontiers in Cancer Endocrinology”

Invited Speaker, “Hormones and Cancer”

AACR Special Meeting on Cancer Prevention, Boston, October

Invited Speaker

International Symposium on IGF binding proteins, Tubingen, Germany, October

Invited Speaker

Chagnon Foundaton, International Cancer Prevention Symposium, Montreal, November

Speaker and Chairman, Scientific Committee

Canadian Breast Cancer Research Initiative, Scientific Retreat, Toronto, November

Invited Participant

2003

Procyon Biopharma, Montreal, January

Invited Speaker

“Novel Therapeutic Targets” Symposium, Monte Carlo, February

Invited Speaker

International Agency for Research on Cancer (IARC), Lyon, February

Invited Speaker

Gordon Conference on “IGFs in Health and Disease”, Ventura Beach, March

Invited Speaker

Prostate Cancer Prevention Trial, Translational Science Project, San Diego, April

Invited Speaker

Novartis Pharma Global Oncology Advisory Board, New Jersey, April

Invited Speaker

AACR Annual Meeting, Washington D.C., July

Invited Speaker: “Meet-the-Expert” Sunrise Session: Insulin, IGFs, and neoplasia

Epidemiology Department, Johns Hopkins University, August

Invited Speaker

Novartis Foundation Symposium, London, October

Invited Speaker: “Biology of IGF-I: interaction with insulin in health and malignancy”

2004

South West Oncology Group, San Antonio, January

Invited Speaker

Aventis Pharma, Paris, January

Invited Speaker

Merck, Rahaway, New Jersey, January

Invited Speaker

Novartis Pharma, Basel, February

Invited Speaker

St. Gallen Cancer Prevention Meeting, Switzerland, February

Invited Speaker and Member of Organizing Committee

American Association for Cancer Research, Orlando, March

Invited Speaker and moderator of a ‘Forum’ on “IGF-I: roles in aging, cancer risk, and cancer treatment”

Scherring Plough Research Institute, New Jersey, September

Invited Speaker

Prostate Cancer Fundation (CAPCURE), Lake Tahoe, October,

Invited Plenary Speaker

Endocrinology Ground Rounds, University of Toronto, Toronto, November

Invited Speaker

2005

Pfizer Research Institute, Groton CT, January

Invited Speaker ‘Targeting the IGF-R and downstream pathways: from lab to clinic’

M.D. Anderson Cancer Center, Huston, TX, January

Invited Speaker ‘Influence of body composition on cancer prognosis: mechanisms’

Gordon Research Conference, “IGFs in Health and Disease”, Ventuna Beach, March

Session Chair

International Symposium on Targeted Cancer Therapies, Amsterdam, March

Invited Speaker

University of Colorado, Denver, Oncology Rounds, March

Invited Speaker

South West Oncology Group, Denver, April

Invited Speaker

Canadian Prostate Cancer Research Network, Vancouver, May

Invited Speaker

Sunnybrooke Hospital, Prostate Cancer Research Center, Toronto, May

Invited Speaker

Astra-Zeneca Advisory Board, Vancouver Island, July

Invited Speaker

Prostate Cancer Foundation (CAPCURE), Phoenix, September

Invited delegate

IGF-I Receptor Targeting Specialist Meeting, Sicily, Italy, November

Invited Speaker

M.I.T. hosted “cohort Consortium” working group, Boston, Novemeber

Invited delegate

NCI (USA) Prostate Cancer Biomarkers Workshop, Denver, December

Invited Speaker

2006

3^rd Annual European Cancer Prevention Meeting, St. Gallen, Switzerland, February

Program Committee and Invited Speaker

“Keystone Conference” New Molecular insights concerning carcinogenesis and cancer prevention, Colorado, March

Invited Speaker

‘Nutritional and Metabolic cancer risk factors’, Harvard Medical School, Boston, March

Invited speaker

Cancer Care Ontario Cohort Planning Meeting, Toronto, March

Invited participant

Prostate Cancer Prevention Trial / SWOG Group Meeting, Salt Lake City, April

Invited speaker

Canadian Breast Cancer Research Alliance “Reasons for Hope” Conference, Montreal, May

Invited Plenary speaker

Canadian Prostate Cancer Research Initiative, Biomarkers Workshop, Niagara Falls, May

Invited speaker

Canadian Breast Cancer “Weekend to end breast cancer” workshop, Vancouver, June

Invited Speaker

ASCO meeting, Podium Presentation, Breast Cancer Session, Atlanta, June

Lecture

MD Anderson Cancer Centre, Houston, June

Invited speaker

Harvard University, Dept. of Nutrition, Boston, October

Invited Speaker

Sanofi Aventis, Paris, October

Invited speaker

Prostate Cancer Foundation (USA), Arizona, October

Invited Speaker

Harvard – McGill Milk symposium, Boston, October

Co- Organizor and speaker

AACR Cancer Prevention Meeting, Boston, November

Invited Speaker

Department of Endocrinology, University of Toronto, November

Invited Speaker

Department of Endocrinology, UCLA, December

Invited Speaker

2007

Prostate Cancer Foundation of Canada, Hockley Valley, Ontario, January

Invited Speaker

Gordon Research Conference, Ventura beach, California, March

Speaker

Endocrinology Rounds, Royal Victoria Hospital, Montreal, May

Invited speaker

ASCO Annual Meeting, educational session, Los Angeles, June

Invited Speaker

Endocrine Society Annual Meeting, Toronto, June

Invited Speaker

“Weekend to End Breast Cancer” Scientific Symposium, Toronto, July

Invited Speaker

“Molecular Targeting in Oncology” Symposium, Washington DC, August

Invited Speaker

Amgen Pharmaceuticals Retreat, Washington DC, August

Invited Speaker

US Army Prostate Cancer Research Program Symposium, Atlanta, September

Invited Speaker

Canadian Prostate Cancer Foundation Scientific Meeting, Toronto, September

Invited Speaker

Astra Zeneca Pharma, San Francisco, September

Invited Speaker

Antibody Therapy in Oncology, Quebec, September

Invited Speaker

Medical Oncology Rounds, Cancer Control Agency of BC, October

Invited Speaker

Amgen Pharma, Thousand Oaks, California, October

Invited Speaker

Abbott Pharmaceuticals, Abbott Park, Chicago, October

Invited Speaker

Prostate Cancer Foundation (Capcure) Annual Scientific Retreat, Lake Tahoe, October

Invited Plenary Speaker

Astra-Zeneca Pharma, Boston, November

Invited Speaker

Pfizer (Endocrinology), Miami, November

Invited lecture to clinical trials group

University Lund, Sweden, November

Invited Speaker and visiting Professor

Bristol Myers Squibb, New York, December

Speaker/organizer, meeting of academic consultants

AACR Cancer Prevention Meeting, Philadelphia, December

Invited Speaker

Annual San Antonio Breast Cancer Symposium, San Antonio, December

Invited Plenary Speaker (audience of 8000)

2008

NCIC Prostate Cancer Alliance, Novel Therapies Symposium, Vancouver, January

Organizing Committee and Speaker

NCIC Clinical Trails Group – Breast and I.N.D. Committees, Toronto, January

Invited participant in clinical trial planning session

ASCO Genito-urinary cancers symposium, San Francisco, February

Invited Plenary speaker (declined)

Pfizer Global Research, New York, February Advisors’ Meeting

Invited Speaker

AACR-NCI Conference on Energetics and Cancer, Washington DC, February

Invited Speaker

University of Toronto, Department of Surgery, Toronto, February

Invited Speaker

3 rd European Cancer Prevention Meeting, St Gallen, Switzerland, March

Invited Plenary Speaker

NCI-EORTC “Targeted Therapy in Oncology” Meeting, Washington, March

Invited Plenary Speaker

Canadian Breast Cancer Research Alliance, Reason for Hope Conference, Vancouver, April

Invited Plenary Speaker

Joint United Kingdom – Canadian prostate cancer symposium, Toronto, June

Invited Speaker

Harvard University – Massachusetts General Hospital, Boston, June

Invited Speaker

European Spring Oncology Conference (ESOC-V), Málaga, Spain, June

Invited Speaker

PACRIM Cancer Symposium, Whistler, BC, August

Invited Speaker

ASCO Breast Cancer Symposium, Washington DC, September

Invited Speaker

European Society of Medical Oncology Annual Meeting, Stockholm, September

Invited Speaker

Southern Italian Oncopathology Meeting, University of Calabria, September,

Invited Speaker

NCI Cancer Prevention Branch Symposium, Bethesda, MD, September

Invited Speaker

Weitzman Institute Oncology Research Groups, Israel, October

Invited Speaker

University of Nice / INSERM Cancer Therapeutics symposium, Nice, October

Invited Speaker

International Symposium of Princess Takamatsu Cancer Research Fund, Tokyo, November

Invited Speaker

2009

NIH/NCI Cancer Prevention Symposium, Washington DC, February

Invited Speaker

Gordon Conference ‘Insulin-like growth factors in Health and Disease’, Ventura, California, March

Speaker

NCI-EORTC Targeted therapy meeting, Amsterdam, March,

Invited Speaker

UT MD Anderson Symposium on Cellular Energy, Metabolism and Cancer, Houston, April

Invited Speaker

NCIC Clinical Trial Group meeting, Toronto, May

Invited Speaker

Prostate Cancer Prevention Trial – NCI P01 Program, Chicago, May

Invited Speaker

Terry Fox Research Institute Research Symposium, Vancouver, May

Invited Speaker

ASCO (American Society of Clinical Oncology), Orlando, May

Invited Faculty and Speaker

Pituitary Society, Washington, DC, June

Invited Speaker

NCI (USA) Special Conference on Cancer Energetics, Bethesda, MD, July

Invited Speaker

Novo Nordisk, Copenhagen, Denmark, August

Invited speaker

Beckman Corporation – Diagnostic Systems Laboratories, Houston, August

Invited Speaker

Sanofi Aventis

Expert panel on insulin and neoplasia, Providence, Rhode Island, August

Imclone Systems Ltd

Global consensus advisory board regarding targeted therapies, London, UK, October

Invited Speaker

Prostate Cancer Foundation (USA) Scientific Retreat, Lake Tahoe, NV, Sept

Session Chair and Invited Speaker

Klinische Forschergruppe sponsored International meeting on molecular GI cancer treatment, Gottingen University, Germany, September

Invited Speaker

Prostate Cancer Prevention Trial, External Advisory Board Meeting, Chicago, September

Participant

AACR Symposium on cancer energetics, San Diego, September

Invited Speaker (delegated to student)

Institut de Cancerologie Gustove Roussy, Villejuif (Paris), November

Invited Speaker

Spanish National Cancer research Centre-sponsored conference: “Energy of Cancer”, Madrid, November

Speaker

Joint American Cancer Society – American Diabetes Association meeting on cancer, insulin and diabetes, Atlanta, December

Invited Speaker

2010

AACR special meeting on targeted therapies in lung cancer, San Diego, January

Invited Plenary Speaker

AACR special meeting on protein translation and neoplasia, San Diego, February

Invited Plenary Speaker

Targeted therapies in pulmonary oncology workshop, Santa Monica, CA, February

Invited Speaker

Asian Targeted Therapy Congress, Tokyo, Japan, March

Invited Speaker

International Congress of Endocrinology, Kyoto, Japan, March

Invited Speaker DECLINED

International Symposium on LKB1/AMPK and cancer energetics, Marseilles, May

Invited Speaker

UK Cancer Research Meeting, Edinburgh, Scotland, June

Keynote Speaker

Novo-Nordisk, Copenhgagen, June

Invited lecture

“eurocancer 2010” , Paris, France, June

Invited Speaker

6^th annual european spring oncology conference (‘ESCOC-6’) Marbella, Spain, June

Invited Speaker

Prostate Cancer Foundation (USA) collaboration presentation, Boston, July

Australia – Canada Prostate Cancer Foundations joint Symposium, Gold Coast, Australia, August

Invited Speaker and Session Chair

NIH, Washington DC, August

Invited Speaker

European Society for Study f Diabetes (EASD) annual meeting, Stockholm

Invited speaker

Insulin Receptor Biology Symposium, Genoa, Italy, October

Invited Speaker (declined)

Thought leaders in cancer energetics meeting, Banbury Centre, Cold Spring Harbor, NY, October

Invited Speaker

LKB1, AMPK, and Cancer Energetics Symposium, Kyoto, Japan, October

Invited Speaker

National Cancer Institute (INCa) of France sponsored “International forum on cancer research and treatment”, Assemblee Nationale, Paris, France, November

Invited Speaker

AACR Cancer Prevention Meeting, Philadelphia, PA, November

Invited Speaker

International Symposium on the insulin receptor, Naples, Italy, November

Invited speaker

“Diabetes and Cancer symposium”, Paris, France, December

Invited Speaker

2011

Grand Rounds, Department of Gynecology, Jewish General Hospital, Montreal, Canada, January

Invited Speaker

Amgen, Toronto, Canada, January

Invited Speaker

Pacific Rim Prostate Cancer Symposium, Gold Coast, Australia, February

Invited Speaker (declined)

Insulin and neoplasia Symposium, Cancuun, Mexico, February

Invited Speaker

International lung cancer symposium, Sana Monica, February

Invited Speaker

Diabetes update symposium, Beijing, China, February

Invited Speaker

Oncology Grand Rounds, Queens University, Kingston, February

International Symposium on Targeted Anticancer Therapies (TAT), Paris, France, March

Invited Speaker

Diabetes cancer study group symposium, Banff, Alberta, March

Invited speaker (delegated)

American Cancer Society expert group on biorepositories, Atlanta, March

Invited speaker

National Cancer Institute, Bethesda, MD, March

Invited speaker

Rachmiel Levine Symposium, Pasadena, California, March

Invited Speaker (declined)

University of Tubingen, Tubingen, Germany, April

Invited speaker

Boerringer Ingelheim Oncology Drug Develoment Group, Vienna, April

Invited speaker

European Diabetes summit, Barcelona, April

Invited speaker (declined)

National Cancer Institute of Canada clinical trials group lung cancer symposium, Toronto, May

Invited speaker

Novo Nordisk meeting on insulin and cancer, Chicago, May

Invited speaker

MD Anderson Cancer Centre GI oncology group, Houston, May

Invited speaker

Axelar drug development group, Chicago, June

Invited speaker

Cytomx Ltd, San Francisco, June

Invited speaker

US Army Breast Cancer Reseach Program ‘Era of Hope’ meeting, Orlando, August

Invited speaker

European Association for study of diabetes (EASD) 47^th Annual Meeting, Lisbon, September

Invited plenary speaker

Institut Cochin, Universite de Paris, September

Invited speaker

University of Texas Cancer Centre, Dallas, September

Invited speaker (declined)

National Breast Cancer Coalition meeting, Aspen, October

Invited Speaker

AACR “Advances in breast cancer research” meeting, San Francisco, October

Invited speaker

Axelar FDA presentation meeting, New Jersey, October

Invited speaker

Canadian Diabetes Association Annual Meeting, Toronto, October

Invited speaker

Banbury Centre / Cold Spring Harbour small group meeting on metformin and neoplasia, October

Organizer and speaker

Lebanon Endocrinology Society, annual meeting, November

Invited speaker (declined)

University of California (SFO) Dept of Urology, November

Invited Speaker

Quebec endocrinology society annual meeting, November

Invited speaker (declined)

Bronfman Oncology Lecture Series, McGill University, Montreal, November

Invited Speaker

San Antonio Breast Cancer Symposium, San Antonio, December

Invited Plenary Speaker

2012

Translational Research on Energetics and Cancer (TREC) group, Philadelpha, January

Invited participant

Cancer and diabetes study group, Brussels, February

Invited speaker

International Congress of Endocrinology (ICE) Annual meeting, Florence, May

Invited Speaker

European Society for Medical Oncology (ESMO), Brussels, May

Invited Speaker

“Biomed Central” symposium on “diet, metabolism, and disease” Washington DC, June

Co-organizer and speaker

German Cancer Research Institute, Heidelberg, November

Invited Speaker

Research keywords and interests: pathophysiology, epidemiology, biomarkers, insulin, IGF.